Document:

Prepared by R.R. Donnelley Financial -- EX-10.14

 Exhibit 10.14 

*** Confidential Treatment Requested. Confidential portions of this document have been redacted and have been 

separately filed with the Securities and Exchange Commission. 

PCR 
 PATENT LICENSE AGREEMENT 

BY AND BETWEEN 
 ROCHE MOLECULAR
SYSTEMS, INC. 
 AND 

EXPRESSION DIAGNOSTICS 

 PATENT LICENSE AGREEMENT 

(HUMAN) 
 CONTENTS 

 

							
	 	  	 	  	Page	 
	Background	  		  	 	2	  
			
	Section 1	  	Definitions	  	 	3	  
			
	Section 2	  	Grant	  	 	5	  
			
	Section 3	  	Additional Limitations & Acknowledgment re Diagnostic Products	  	 	6	  
			
	Section 4	  	Royalties, Records and Reports	  	 	6	  
			
	Section 5	  	Technology Notification	  	 	8	  
			
	Section 6	  	Diligence	  	 	8	  
			
	Section 7	  	Term and Termination	  	 	8	  
			
	Section 8	  	Confidentiality-Publicity	  	 	10	  
			
	Section 9	  	Compliance	  	 	11	  
			
	Section 10	  	Assignment	  	 	11	  
			
	Section 11	  	Negation of Warranties and Indemnity	  	 	12	  
			
	Section 12	  	General	  	 	12	  
			
	Attachments:	  		  			
			
	Attachment I	  	List of Licensed Technology	  			
			
	Attachment II	  	Combination Services	  			
			
	Attachment III	  	Summary Royalty Report Form	  			
			
	Attachment IV	  	Collection Rate	  			

  
 1 

 PATENT LICENSE AGREEMENT 

(Human) 
 This Agreement is made
by and between 
 Roche Molecular Systems, Inc., 4300 Hacienda Drive, Pleasanton, California 94588 

(hereafter referred to as “RMS”) 

and 
 Expression Diagnostics, 750
Gateway Boulevard, South San Francisco, California 94080 
 (hereafter referred to as “ED”) 

hereafter individually referred 

to as a “Party” or collectively as “The Parties” 

******** 
 BACKGROUND 

 

	A.	RMS owns and has the right to grant licenses to practice under certain United States Patents describing and claiming, inter alia, nucleic acid amplification processes known as polymerase chain reaction
(“PCR”), homogeneous PCR, and RT-PCR (“reverse transcription PCR”). 

  

	B.	ED desires to obtain a non-exclusive license from RMS to use the Licensed Technology to perform certain PCR-based human in vitro clinical laboratory services, and RMS is willing to grant such a license
to ED on the terms and subject to the conditions provided exclusively in this Agreement. 

  
 2 

 NOW, THEREFORE, for and in consideration of the mutual covenants contained herein, RMS and ED agree as follows:

  

	1.	Definitions 

 For the purpose of this Agreement, and solely for that purpose, the terms set forth
hereinafter shall be defined as follows: 
  

	1.1	The term “Affiliate” shall mean with respect to a given Party: 

  

	 	a)	an organization which, directly or indirectly, controls such Party; 

  

	 	b)	an organization which is, directly or indirectly, controlled by such Party; or 

  

	 	c)	an organization which is controlled, directly or indirectly, by the ultimate parent company which controls, directly or indirectly, such Party. 

For purposes of this paragraph, “control” shall mean the ownership of fifty percent (50%) or more of the voting stock or equity
interests of an organization or otherwise having the power to govern or direct the financial and the operating policies or to appoint the management of such organization. 

With respect to RMS, the term “Affiliate” shall not include Genentech, Inc., 1 DNA Way, South San Francisco, California 94080-4990,
U.S.A. (“Genentech”) nor Chugai Pharmaceutical Co., Ltd, 1-9, Kyobashi 2-chome, Chuo-ku, Tokyo, 104-8301 Japan (“Chugai”). 
  

	1.2	“Combination Service” shall mean a Licensed Service offered in combination with another non-PCR testing service or together with a non-testing service(s) such as a specialized interpretive service
or a consultative service (e.g., genetic counseling) as part of a package, where the Licensed Service is not separately billed. 

  

	1.3	“Diagnostic Product” shall mean an assemblage of reagents, including but not limited to reagents packaged in the form of a kit, useful in performing a Licensed Service. 

 

	1.4	“Effective Date” shall mean the date on which the last signatory to this Agreement signs this Agreement. 

  

	1.5	“Licensed Field” shall mean the field of clinical laboratory services that detect the presence, absence and/or quantity of a nucleic acid sequence for the detection, diagnosis, confirmation,
prognosis, management and/or treatment of a human disease or condition, including, but not limited to, such services: to identify predisposition to disease, disease susceptibility, confirm disease, predict therapeutic effectiveness or monitor
disease progress; used in the course of human clinical trials; for Parentage Determination; and for tissue transplant typing, including testing performed on animal tissue intended for use in xenotransplantation. Licensed Field shall specifically
exclude any services performed for the screening of blood and/or blood products. 

  
 3 

	1.6	“Licensed Service(s)” shall mean the performance by ED of an in vitro procedure within the Licensed Field which utilizes the Licensed Technology. Licensed Services include, but are
not limited to, any combination of the steps of collecting a sample for analysis, isolating nucleic acid sequences from the sample, amplifying one or more desired sequences, analyzing the amplified material, including sequence analysis, and
reporting the results. 

  

	1.7	“Licensed Technology” shall mean, subject to the following limitations, the Valid Claims of the United States patents listed in Attachment I to this Agreement and any reissue or reexamination
patents thereof. No rights under any kit claims of such patents are included in this definition or licensed under this Agreement. With the exception of the reaction mixture claims of United States Patents Nos. 5,804,375, 5,693,517, 5,476,774 and
6,127,155, the plasmid claims of the 5,476,774 patent, the primer claims of United States Patent No. 5,573,906, and the probe claims of United States Patent No. 5,110,920, no rights under any apparatus, device, composition of matter,
reagent or substance claims of such patents are included in this definition or licensed under this Agreement. 

  

	1.8	“Net Service Revenues” shall mean the gross invoice price for the Licensed Services performed by ED (or the fair market value for any nonmonetary consideration which ED agrees to receive in
exchange for Licensed Services), less the following deductions where they are factually applicable and are not already reflected in the gross invoice price: 

  

	 	a)	discounts allowed and taken, in amounts customary in the trade (which shall include the difference between the dollar amount charged by ED for a Licensed Service and the Medicare and/or Medicaid Limits of Allowance
and/or reimbursement limitations of a Third Party insurance program); and 

  

	 	b)	actual bad debt which bad debt ED can prove and document that it was reasonable and diligent in its efforts to collect payment. 

  

	 	1.8.1	The Net Service Revenues of those Licensed Services that are performed by ED for any person, firm or corporation controlling, controlled by or under common control with ED, or enjoying a special course of dealing with
ED, shall be determined based on the average selling price of such Licensed Services to all Third Parties during the period in question. 

  

	 	1.8.2	 It is hereby understood and agreed that, to the extent feasible, Licensed Services and Combination Services shall at all times be invoiced, listed and
billed by ED as a separate item in ED’s invoices, bills and reports to customers. Net Service Revenues for determining royalties with respect to a Licensed Service which is part of a Combination Service shall be determined by multiplying the
gross invoice price of the Combination Service, less applicable deductions, by the appropriate fraction in Attachment II hereto. The fraction specified in Attachment II for a particular Licensed Service included in a Combination Service shall be set
by RMS after consultation 

  
 4 

	 	
with ED, as accurately reflecting the value contributed by the Licensed Service to the overall value of the Combination Service as offered by ED, and as provided in Section 2.4. Attachment
II hereto shall be modified as new Combination Services are identified and new royalty-bearing fractions set, and as set forth in Section 2.4. 

  

	1.9	“Parentage Determination” shall mean analysis of human genetic material to ascertain whether two or more individuals are biologically related, but specifically excludes analysis of forensic
evidence for a sexual assault investigation. 

  

	1.10	“Territory” shall mean the United States and its possessions and the Commonwealth of Puerto Rico. 

  

	1.11	“Third Party” shall mean an entity other than an Affiliate of either Party to this Agreement. 

  

	1.12	“Valid Claim” shall mean a claim of a patent which has not expired or been disclaimed, cancelled, held invalid or held unenforceable by a decision of a court or other governmental agency of
competent jurisdiction, from which no further appeal is possible or has been taken within the time period provided under applicable law for such an appeal. 

  

	2.	Grant 

  

	2.1	Grant. Upon the terms and subject to the conditions and restrictions of this Agreement, RMS hereby grants to ED, and ED hereby accepts from RMS, a royalty-bearing, non-exclusive, personal, non-transferable
license under the Licensed Technology solely to perform Licensed Services within the Territory. 

  

	2.2	Performance of Licensed Services Only. The Licensed Technology may be used solely for the performance of Licensed Services and for no other purpose whatsoever, and no other right, immunity or license is granted
to ED expressly, impliedly or by estoppel. 

  

	2.3	Personal License. ED expressly acknowledges and agrees that the license granted hereunder is personal to ED alone and ED shall have no right to sublicense, assign or otherwise transfer or share its rights under
the foregoing license. 

  

	2.4	Combination Service(s). For each Combination Service that ED intends to offer pursuant to this Agreement, and at least sixty (60) days before ED intends to offer any such Combination Service, ED shall:

  

	 	a)	notify RMS of such proposed Combination Service, such notice to include a complete and detailed description of the proposed Combination Service; and 

 

	 	b)	obtain from RMS a duly authorized agreement, in the form of Attachment II hereto, for such Combination Service, which agreement shall indicate the fraction or 

  
 5 

 *** Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
 percentage of the package price of such Combination Service, less appropriate deductions, on which royalties shall be paid
hereunder. 
 For any Combination Service(s) for which ED has not satisfied the criteria set forth in subsections (a) and
(b) above, the royalty payable on such Combination Service shall be assessed on 100% of the package price of such Combination Service, less applicable deductions. As to all other Licensed Services offered by ED which are not part of a
Combination Service, ED agrees to inform RMS of the availability from ED of each such Licensed Service within thirty (30) days after ED commences offering the Licensed Service. 

 

	2.5	Credit for Licensed Technology Rights. RMS hereby grants to ED the right and ED accepts and agrees to credit RMS as the source of its Licensed Technology rights in ED’s promotional materials and any other
materials intended for distribution to Third Parties as follows: 

 “This service is performed pursuant to an agreement
with Roche Molecular Systems, Inc.” 
  

	3.	Additional Limitations and Acknowledgment Regarding Diagnostic Products 

 ED acknowledges and agrees that
the license rights granted hereunder are for the performance of Licensed Services only and do not include any right to make, have made, import, offer to sell or sell any products, including apparatuses, devices, PCR reagents, kits or Diagnostic
Products. ED further acknowledges and agrees that RMS and its Affiliates are in the business of providing clinical laboratory testing services and the commercial sale of diagnostic testing systems, kits and reagents and therefore may compete
directly with ED’s business. 
  

	4.	Royalties, Records and Reports 

  

	4.1	Royalties. For the rights and privileges granted under Section 2.1 of this Agreement, ED shall pay to RMS royalties equal to [***] percent ([***]%) of ED’s Net Service Revenues. 

No royalty is due on PCR-based assays performed solely for the purpose of evaluating a procedure to be used as a Licensed Service after
validation. 
 No royalty is due on assays performed with Roche labeled diagnostic kits or Third Party diagnostics kits licensed by Roche,
which convey human diagnostic label license rights to end users. 
  

	4.2	Reports. ED shall deliver to RMS, within forty-five (45) days after the end of and for each quarterly calendar period during the Term, i.e. the three (3) month periods that are January 1 through
March 31, April 1 through June 30, July 1 through September 30, and October 1 through December 31 (each a “Reporting Period”), a true and accurate royalty report (“Royalty Report”).
Each Royalty Report shall indicate the number of Licensed Services performed during the relevant Reporting Period and the detail specified on the “Summary Royalty Report,” a copy of which is attached hereto as Attachment III, or on a form

  
 6 

 generated by ED which duplicates the format of the Summary Royalty Report. If no royalties are
due for a given Royalty Period, it shall be so reported. The correctness and completeness of each Royalty Report shall be attested to in writing by an authorized representative of ED. 

In the event ED is unable to calculate Net Service Revenues as prescribed in Section 1.8, ED shall so inform RMS, and upon RMS’s
written consent, ED shall calculate royalties as follows: 
 Upon receipt by RMS of satisfactory documentation verifying ED’s actual
percentage of gross billings for Licensed Services and/or Combination Services collected for ED’s most recently ended fiscal year (the “Collection Rate”), subject to the provisions of Section 2.4 above, ED shall be permitted to
calculate Net Service Revenues taking into account the Collection Rate. As of the Effective Date, ED hereby represents and confirms to RMS that its Collection Rate for its fiscal year ending NA was NA percent (NA%),
which rate is specified in Attachment IV. During the Term of this Agreement, and within ninety (90) days after the end of each ED fiscal year, ED shall deliver to RMS satisfactory documentation that verifies the then Collection Rate. If
ED’s Collection Rate varies by at least five percent (5%) from the rate stated in Attachment IV, RMS shall amend Attachment IV accordingly. Should ED fail to provide the required updated documentation, ED shall calculate Net Service
Revenues and royalties due as prescribed in Sections 1.8 and 2.4 for the remaining Term of the Agreement. 
 Simultaneously with the delivery
of each Royalty Report, ED shall pay to RMS the royalty due under this Agreement for the period covered by such report. All payments due RMS hereunder shall be payable in United States currency and sent together with the Royalty Report by the due
date to the following address: 
 Roche Molecular Systems, Inc. 

P.O. Box 100858 
 Pasadena, CA
91189-0858 
 or to any other address that RMS may advise in writing. 

 

	4.3	Inspection. Within ten (10) days after RMS’s written request to ED, an accounting firm selected by RMS (including, but not limited to, RMS’s normal certified public accounting firm), may, at
RMS’s own expense (except as provided below), inspect the records, books of account and any other materials of ED pertaining to the transactions and matters contemplated by this Agreement and/or the Royalty Reports required in Section 4.2
above, provided that any accounting firm will hold such records in strict confidence, except as necessary to report to RMS and ED on ED’s compliance with the terms, conditions and restrictions of this Agreement. If such an inspection shows an
underpayment by ED to RMS by more than ten percent (10%) for any Reporting Period, ED will pay, in addition to the amount due, plus interest, the accounting firm’s reasonable fees and expenses. 

  
 7 

	4.4	Prior Licensed Services. Licensed Services performed by ED prior to execution of this Agreement shall be subject to the royalties described in this Agreement and shall be reported and due to RMS with the first
Royalty Report due provided under Section 4.2. Provided, however, that where this Agreement replaces an existing license agreement, the royalty obligations of ED under this Agreement commence the first day of the month in which this Agreement
is executed. 

  

	4.5	Past Due Amounts Bear Interest. If ED shall fail to pay any amount specified under this Agreement after the due date thereof, the amount owed shall bear interest at the lower of (i) the Citibank, N.A. base
lending rate (aka, the “Prime Rate”), or (ii) the maximum rate allowed by applicable law, from the due date until paid. 

  

	4.6	Survival. The provisions of this Section 4 shall survive any termination or expiration of this Agreement. 

  

	5.	Technology Notification 

  

	5.1	Notification. With respect to any invention, improvement or discovery (hereinafter referred to as “Discoveries” in this Section) of ED made after entering into this Agreement and resulting from work
conducted under or in conjunction with this Agreement and being applicable to the Licensed Technology, if ED decides to license said Discoveries to Third Parties, then ED agrees to provide to RMS, unless not possible due to ED’s pre-existing
commitments to Third Parties relating to said Discoveries, a reasonable opportunity to negotiate a license to use said Discoveries in PCR-based Diagnostic Products and services. Such Discoveries may include, but are not limited to, improvements of
the Licensed Technology or in the performance of Licensed Services, modifications to or new methods of performing the Licensed Services, including the automation of the PCR process or of the Licensed Services. 

 

	5.2	Agreement re Discovery. Any agreement reached between The Parties as a result of ED’s notification to RMS of a Discovery pursuant to Section 5.1 hereto shall be upon terms and conditions negotiated in
good faith by The Parties. 

  

	6.	Diligence 

 ED shall exercise reasonable diligence in developing, testing, validating,
documenting, promoting and performing the Licensed Services. In the course of such diligence, ED shall implement appropriate procedures and take appropriate steps including, upon reasonable written request of RMS, furnishing RMS with representative
copies of all promotional material relating to the Licensed Services. 
  

	7.	Term and Termination 

  

	7.1	Term of Agreement. This Agreement shall commence on the Effective Date and, unless terminated earlier as provided herein, shall terminate on the date of expiration of the last to expire of the patents included
within the Licensed Technology, which patent contains at least one Valid Claim covering the performance of a Licensed Service. 

  
 8 

	7.2	ED Termination for Convenience. Notwithstanding any other Section of this Agreement, ED may terminate this Agreement for any reason on thirty (30) days’ written notice to RMS. 

 

	7.3	Termination for Change of Control, Etc. RMS shall have the right to terminate this Agreement and the license rights granted herein immediately upon written notice to ED upon any material change in the ownership
or control of ED or of its assets or in the event ED breaches the provisions of Section 10 below. 

  

	7.4	Termination for Insolvency, Etc. This Agreement and the license rights granted hereunder to ED shall automatically terminate upon: (a) an adjudication of ED as bankrupt or insolvent, or ED’s admission
in writing of its inability to pay its obligations as they mature; or (b) an assignment by ED for the benefit of creditors; or (c) ED’s applying for or consenting to the appointment of a receiver, trustee or similar officer for any
substantial part of its business or property, or such a receiver, trustee or similar officer’s appointment without the application or consent of ED, if such appointment shall continue in effect for a period of ninety (90) days; or
(d) ED’s instituting (by petition, application, answer, consent or otherwise) any bankruptcy, insolvency arrangement or similar proceeding relating to ED or its business or property under the laws of any jurisdiction; or (e) the
institution of any such proceeding (by petition, application, answer, consent or otherwise) against ED, if such proceeding shall remain in effect for a period of ninety (90) days; or (f) the issuance or levy of any judgment, writ, warrant
of attachment or execution or similar process against a substantial part of the property of ED, if such judgment, writ, or similar process shall not be released, vacated or fully bonded within ninety (90) days after its issue or levy; or
(g) the loss of ED’s federal or state licenses, permits or accreditation necessary for the operation of ED as a health care institution. 

  

	7.5	Termination for Change of Status. If ED is a government institution or a non-profit entity, this Agreement and the license rights granted to ED herein shall automatically terminate within thirty (30) days of
ED’s reclassification as a non-government institution, or as a for-profit entity pursuant to the applicable provisions of the United States Internal Revenue Code, 26 U.S.C. Upon such termination, ED may request a new license pursuant to the
same terms and conditions then being offered to other for-profit institutions, although RMS is not obligated by anything contained in this Agreement to grant such a license. 

 

	7.6	Termination for Breach. Upon any breach of or default by ED of a material term under this Agreement, RMS may terminate this Agreement upon thirty (30) days’ written notice to ED. Said termination
shall become effective at the end of the thirty-day period, unless during said period ED fully cures such breach or default. 

  

	7.7	Effects of Termination. Upon termination of this Agreement as provided herein, all license rights and immunities granted to ED hereunder shall terminate and revert to or be retained by RMS. To the extent RMS has
licensed technology or know-how of ED pursuant to 

  
 9 

 Section 5 hereto; those licenses shall remain in force according to their terms. Other
provisions of this Agreement which by their nature would reasonably be expected to survive termination shall so survive. Termination of this Agreement shall not relieve either Party from any duty or obligation that had accrued prior to termination.
Each Party shall retain all of its rights and remedies in respect of any breach or default by the other party of the terms, conditions and provisions of this Agreement. 
  

	7.8	Duty to Report and Pay Royalties Survives. ED’s obligations to report to and pay royalties to RMS as to the Licensed Services performed under the Agreement prior to termination or expiration of the Agreement
shall survive such termination or expiration. 

  

	8.	Confidentiality-Publicity 

  

	8.1	Publicity. Except as otherwise specifically provided in Section 2.5, ED agrees to obtain RMS’s written approval before distributing any written information, such as a press release, to Third Parties
which contains references to RMS or this Agreement. RMS’s approval shall not be unreasonably withheld or delayed and, in any event, RMS’s decision shall be rendered within three (3) weeks of receipt of the written information. Once
approved, such materials, or abstracts of such materials, which do not materially alter the context of the material originally approved may be reprinted during the Term of the Agreement without further approval by RMS unless RMS has notified ED in
writing of its decision to withdraw permission for such use. 

  

	8.2	Confidentiality Obligations. Each Party agrees that any financial, legal or business information or any technical information marked “Confidential” or “Proprietary” and disclosed to it (the
“Receiving Party”) by the other (the “Disclosing Party”) in connection with this Agreement, shall be considered the confidential and proprietary information of the Disclosing Party, and the Receiving Party shall not disclose same
to any Third Party and shall hold it in confidence for a period of five (5) years and will not use it other than in the performance of this Agreement, provided, however, that any information, know-how or data which is orally disclosed to the
Receiving Party shall not be considered confidential and proprietary unless such oral disclosure is stated to be confidential or proprietary prior to disclosure and is reduced to writing and given to the Receiving Party in written form within thirty
(30) days after the oral disclosure thereof. Such confidential and proprietary information shall include, without limitation, marketing and sales information, commercialization plans and strategies, research and development work plans, and
technical information such as patent applications, inventions, trade secrets, systems, methods, apparatus, designs, tangible material, organisms and products and derivatives thereof. 

 

	8.3	Exceptions. The above obligations of confidentiality and restrictions on use shall not be applicable to the extent: 

  

	 	a)	such information is general public knowledge or, after disclosure hereunder, becomes general or public knowledge through no fault of the Receiving Party; 

  
 10 

	 	b)	such information can be shown by the Receiving Party by its written records to have been in its possession, with no obligation of confidentiality to a Third Party, prior to receipt thereof hereunder; 

 

	 	c)	such information is received by the Receiving Party from any Third Party for use or disclosure by the Receiving Party without any obligation of confidentiality or restriction on use, provided, however, that information
received by the Receiving Party from any Third Party funded by the Disclosing Party (e.g. consultants, subcontractors, etc.) shall not be released from confidentiality under this exception; 

 

	 	d)	such information was independently developed by the Receiving Party without use of the information of the Disclosing Party; or 

  

	 	e)	the disclosure of such information is required or desirable to comply with or fulfill applicable law or court process, governmental requirements, submissions to governmental bodies, or the securing of regulatory
approvals. 

  

	8.4	Confidentiality of Agreement. Each Party shall, to the extent reasonably practicable, maintain the confidentiality of this Agreement and its provisions and shall refrain from making any public announcement or
disclosure of the terms of this Agreement without the prior written consent of the other Party, except to the extent a Party concludes in good faith that such disclosure is required under applicable law or regulations, in which case the other Party
shall be notified in advance. 

  

	9.	Compliance with Law 

 In exercising any and all rights and in performing its obligations hereunder, ED
shall comply fully with any and all applicable laws, regulations and ordinances and shall obtain and keep in effect all applicable licenses, permits and other governmental approvals, whether at the federal, state or local levels, necessary or
appropriate to perform the Licensed Services and carry on its activities hereunder and ED hereby agrees to defend, indemnify and hold RMS and its Affiliates harmless from and against any and all liability, demands, damages, expenses (including
attorneys’ and experts’ fees) and losses suffered or incurred by RMS or its Affiliates arising from, resulting from or otherwise concerning any breach by ED of its obligations under this Section 9. ED agrees to refrain from making any
material misstatements or activities about the Licensed Technology licensed hereunder that will have an adverse effect on the business reputation of RMS. RMS may advise ED of any such material misstatements or activities and ED will have thirty
(30) days to correct such material misstatements or activities. 
  

	10.	Assignment 

 This Agreement shall not be assigned or transferred by ED (including by merger, operation of
law or in any other manner including, without limitation, any purported assignment or transfer that 

  
 11 

 
might arise from a sale or transfer of ED’s business or assets) without the express written consent of RMS. RMS may assign all or any part of its rights and obligations under this Agreement
at any time without the consent of ED. ED agrees to execute such further acknowledgments or other instruments as RMS may reasonably request in connection with any such assignment. 

 

	11.	Negation of Warranties and Indemnity 

  

	 	11.1	Nothing in this Agreement shall be construed as: 

  

	 	a)	a warranty or representation by RMS as to the validity or scope of any patent included within the Licensed Technology; 

  

	 	b)	a warranty or representation that the use of the Licensed Technology and/or the performance of Licensed Services are or will be free from infringement of patents of Third Parties; 

 

	 	c)	an obligation to bring or prosecute actions or suits against Third Parties for infringement; or 

  

	 	d)	conferring by implication, estoppel or otherwise any license, right or immunity under any patents or patent applications of RMS other than those patents specified in Licensed Technology, regardless of whether such other
patents and patent applications are dominant or subordinate to the patents in Licensed Technology. 

  

	11.2	RMS MAKES NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT. 

  

	11.3	ED shall assume full responsibility for its use of the Licensed Technology and shall defend, indemnify and hold RMS and its Affiliates harmless from and against all liability, demands, damages, expenses (including
attorneys’ and experts’ fees) and losses for death, personal injury, illness, errors, property damage or any other injury or damage, including any damages or expenses arising in connection with state or federal regulatory action
(collectively “Damages”), arising or resulting from or otherwise concerning the use by ED, including its officers, directors, agents and employees, of the Licensed Technology or the performance of the Licensed Services except, and only to
the extent, that such Damages are caused solely by the negligence or willful misconduct of RMS. 

  

	12.	General 

  

	12.1	Entire Agreement. This Agreement constitutes the entire agreement between The Parties as to the subject matter hereof, and all prior negotiations, representations, agreements and understandings are merged into,
extinguished by and completely expressed by it. This Agreement may be modified or amended only by a writing executed by an authorized officer of each of The Parties. 

  
 12 

	12.2	Notice. Any notice required or permitted to be sent hereunder shall be given by hand delivery, by registered, express or certified mail, return receipt requested, postage prepaid, or by nationally recognized
private express courier or by confirmed facsimile to the other Party at the address listed below, or to such other addresses of which a Party may so notify the other. Notices will be deemed given when hand delivered if by hand delivery, or when
received if by any other authorized method. 

  

			
	If to RMS:	    	Roche Molecular Systems, Inc.
		    	1145 Atlantic Avenue, Suite 100
		    	Alameda, California 94501
		    	Attn: Licensing Department
		
	RMS cc:	    	Roche Molecular Systems, Inc.
		    	1145 Atlantic Avenue, Suite 100
		    	Alameda, California 94501
		    	Attn: Sr. Vice President, General Counsel
		
	If to ED:	    	Expression Diagnostics
		    	750 Gateway Boulevard, Suite H
		    	South San Francisco, CA 94080
		    	Attn: CFO

  

	12.3	Governing Law. This Agreement is subject to and shall be construed and enforced in accordance with the law of the State of California, U.S.A., excluding its conflict of laws rules and except as to any issue
concerning the validity, scope or enforceability of any patent within the Licensed Technology, which issue shall be determined in accordance with the applicable patent laws of the United States. 

 

	12.4	Arbitration. All disputes, claims or controversies arising between the Parties concerning this Agreement or the matters or transactions contemplated herein shall be settled by final and binding arbitration
conducted in San Francisco, California pursuant to the Commercial Arbitration Rules of the American Arbitration Association, in accordance with the following procedural process: 

 

	 	a)	The arbitration tribunal shall consist of three arbitrators. In the request for arbitration and the answer thereto, each Party shall nominate one arbitrator and the two arbitrators so named will then jointly appoint a
third neutral arbitrator as chairman of the arbitration tribunal. If the two arbitrators so named are unable to appoint a third neutral arbitrator, the third neutral arbitrator shall be appointed by the American Arbitration Association in accordance
with the procedures contained in the Commercial Arbitration Rules. 

  
 13 

	 	b)	The decision of the arbitration tribunal shall be final and binding and judgment upon such decision may be entered in any court of competent jurisdiction for judicial acceptance of such an award and enforcement. Each
Party hereby submits itself to the jurisdiction of the courts of the place of arbitration, but only for the entry of judgment with respect to the decision of the arbitrators hereunder. 

 

	12.5	No Conflict with Law. Nothing in this Agreement shall be construed so as to require the commission of any act contrary to law, and wherever there is any conflict between any provision of this Agreement or
concerning the legal right of The Parties to enter into this Agreement and any statute, law, ordinance or treaty, the latter shall prevail, but in such event the affected provisions of the Agreement shall be curtailed and limited only to the extent
necessary to bring it within the applicable legal requirements. In any event, all other provisions of this Agreement shall be deemed valid and enforceable to the fullest extent possible. 

 

	12.6	Superceding Agreement. Concurrent with the execution of this Agreement, and effective as of the Effective Date herein, any existing agreement between The Parties which grants rights to PCR technology to ED to
perform human diagnostic testing services, is hereby superceded and replaced in its entirety by this Agreement. 

 IN WITNESS WHEREOF, The
Parties hereto have set their hands and seals and duly executed this Agreement on the date(s) indicated below, to be effective as of the Effective Date as defined herein. 
  

									
	ROCHE MOLECULAR SYSTEMS, INC.	 		 	EXPRESSION DIAGNOSTICS
					
	By:	 	 /s/ Melinda Griffith
	 		 	By:	 	 /s/ Avi Kulkarni

					
	Name:	 	Melinda Griffith	 		 	Name:	 	 Avi Kulkarni

					
	Title:	 	Sr. Vice President & General Counsel	 		 	Title:	 	 VP & CFO

					
	Date:	 	Nov 8, 2004	 		 	Date:	 	Nov 16, 2004

  

			
	Apprv’d As To Form
RMS LAW DEPT.
		
	By:	 	 /s/ [ILLEGIBLE]

  
 14 

 ATTACHMENT I 

Licensed Technology 
  

			
		
	USP B1 4,683,195	  	Process for Amplifying, Detecting and/or Cloning Nucleic Acid Sequences
		
	USP B1 4,683,202	  	Process for Amplifying Nucleic Acid Sequences
		
	USP 4,965,188	  	Process for Amplifying, Detecting, and/or Cloning Nucleic Acid Sequences Using a Thermostable Enzyme
		
	USP 5,008,182	  	Detection of AIDS Associated Virus by PCR
		
	USP 5,110,920	  	HLA Typing Method and DNA Probes Used Therein
		
	USP 5,176,995	  	Detection of Viruses by Amplification and Hybridization
		
	USP 5,210,015	  	Homogeneous Assay System Using the Nuclease Activity of a Nucleic Acid Polymerase
		
	USP 5,219,727	  	Quantitation of Nucleic Acids Using PCR
		
	USP 5,310,652	  	Reverse Transcription With Thermostable DNA Polymerases — High Temperature Reverse Transcription
		
	USP 5,322,770	  	Reverse Transcription with Thermostable DNA Polymerases — High Temperature Reverse Transcription
		
	USP 5,389,512	  	Method for Determining the Relative Amount of a Viral Nucleic Acid Segment in a Sample by the PCR
		
	USP 5,407,800	  	Reverse Transcription with Thermus thermophilus Polymerase
		
	USP 5,476,774	  	Quantitation of Nucleic Acids Using PCR (limited to claims 1-4,8,9,15-18)
		
	USP 5,487,972	  	Nucleic Acid Detection by the 5’-3’ Exonuclease Activity of Polymerases Acting on Adjacently Hybridized Oligonucleotides
		
	USP 5,491,063	  	Methods for In-Solution Quenching of Fluorescently Labeled Oligonucleotide Probes
		
	USP 5,561,058	  	Methods for Coupled High Temperatures Reverse Transcription and PCR
		
	USP 5,571,673	  	Methods for In-Solution Quenching of Fluorescently Labeled Oligonucleotide Probes
		
	USP 5,573,906	  	Detection of Nucleic Acids Using a Hairpin Forming Oligonucleotide Primer and an Energy Transfer Detection System (claims 13 -15 excluded)
		
	USP 5,618,703	  	Unconventional Nucleotide Substitution in Temperature Selective RT-PCR
		
	USP 5,677,152	  	Amplification Using a Reversibly Inactivated Thermostable Enzyme (method claims only)
		
	USP 5,693,517	  	Reagents and Methods for Coupled High Temperature Reverse Transcription and Polymerase Chain Reactions
		
	USP 5,773,258	  	Amplification Using a Reversibly Inactivated Thermostable Enzyme (method claims only)
		
	USP 5,804,375	  	Reaction Mixtures for Detection of Target Nucleic Acids
		
	USP 5,994,056	  	Homogeneous Methods for Nucleic Acid Amplification and Detection
		
	USP 6,127,155	  	Stabilized Thermostable Nucleic Acid Polymerase Compositions Containing Non-Ionic Polymeric Detergents
		
	USP 6,171,785	  	Methods and Devices for Homogeneous Nucleic Acid Amplification and Detection

 ATTACHMENT II 

COMBINATION SERVICES 
  

			
	 Licensed Service(s)
	  	Percent of Net Service
Revenues for Combination
Services which is Attributable
to Licensed
Service(s)

  
 [TO BE DETERMINED] 

  
 2 

 ***Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
  

 ATTACHMENT III 

SUMMARY ROYALTY REPORT 

for the Period                      to
                     
  

			
	 Licensee: Expression Diagnostics
  

Effective Date:
	 	 Field of Use: human in vitro services
  

Royalty Rate: [***] of Net Service Revenues

  

													
	 Licensed Service
  

(“Lic. Service”)
	  	Number of
Lic.
Services
Performed	  	Gross
Invoice
Price per
Lic.
Service	  	Allowed
Deductions	  	Combination
Service %
(see Attach II)	  	Net
Service
Revenue	  	Earned
Royalty
		  		  		  		  		  		  	
		  		  		  		  		  		  	
		  		  		  		  		  		  	
		  		  		  		  		  		  	
		  		  		  		  		  		  	
		  		  		  		  		  		  	
		  		  		  		  		  		  	
		  		  		  		  		  		  	
		  		  		  		  		  		  	
	 TOTALS
	  		  		  		  		  		  	

 Check here if there were no Licensed Services performed for this report period:
                     
  

	*	Combination Service %s must be previously agreed upon. To confirm that a Combination Service % has been established or to propose this status, please contact RMS Licensing at (510) 814-2843.

 I hereby certify the information set forth above is correct and complete with respect to the amounts due under the applicable license
agreement. 
  

									
	By:	 	  
	 		 	Title:	 	  

		 	 (authorized signature)
	 		 		 	

									
	Name (please print):	 	  
	 		 	Date:	 	  

 Mail report with any royalty payment due to: 

Roche Molecular Systems, Inc., P. 0. Box 100858, Pasadena, CA 91189-0858 

  
 3 

 ATTACHMENT IV 

COLLECTION RATE 
  

			
	 Fiscal Year
	  	Collection Rate Percentage

  

(Only applicable as provided in Section 4.2) 

  
 4 

 ATTACHMENT 1 

Licensed Technology 
 Page 1 of 2 

 

			
	 USP 4,946,952
	  	Process for isolating nucleic acids
		
	 USP 5,057,410
	  	Chimeric messenger RNA detection methods
		
	 USP 5,063,162
	  	Process for isolating nucleic acids utilizing protease digestion
		
	 USP 5,066,584
	  	Methods for generating single stranded DNA by the polymerase chain reaction
		
	 USP 5,075,216
	  	Methods for DNA sequencing with thermus aquaticus DNA polymerase
		
	 USP 5,091,310
	  	Structure-independent DNA amplification by the polymerase chain reaction
		
	 USP 5,110,920
	  	HLA typing method and DNA probes used therein
		
	 USP 5,210,015
	  	Homogeneous assay system using nuclease activity of a nucleic acid polymerase
		
	 USP 5,219,727
	  	Quantitation of nucleic acids using the polymerase chain reaction
		
	 USP 5,268,268
	  	Detection of HTLVI and HTLVII viruses by hybridization
		
	 USP 5,310,652
	  	Reverse transcription with thermostable DNA polymerase — high temperature reverse transcription
		
	 USP 5,310,893
	  	Method for HLA DP typing
		
	 USP 5,314,809
	  	Methods for nucleic acid amplification
		
	 USP 5,322,770
	  	Reverse transcription with thermostable DNA polymerases — high temperature reverse transcription
		
	 USP 5,389,512
	  	Method for determining the relative amount of a viral nucleic acid segment in a sample by the polymerase chain reaction
		
	 USP 5,407,800
	  	Reverse transcription with thermus thermophilus polymerase .
		
	 USP 5,411,876
	  	Use of grease or wax in the polymerase chain reaction
		
	 USP 5,418,149
	  	Reduction of non-specific amplification glycosylase using dutp and DNA uracil
		
	 USP 5,451,505
	  	Methods for tagging and tracing materials with nucleic acids
		
	 USP 5,451,512
	  	Methods and reagents for HLA Class I A locus DNA typing
		
	 USP 5,468,613
	  	Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids (kit claims excluded)
		
	 USP 5,476,774
	  	Quantitation of nucleic acids using the polymerase chain reaction (kit claims excluded)
		
	 USP 5,487,972
	  	Nucleic acid detection by the 5’-3’ exonuclease activity of polymerases acting on adjacently hybridized oligonucleotides
		
	 USP 5,491,063
	  	Methods for in-solution quenching of fluorescently labeled oligonucleotide probes
		
	 USP 5,541,065
	  	Method for HLA DP typing (kit claims excluded)
		
	 USP 5,501,963
	  	Amplification of nucleic acids in blood samples
		
	 USP 5,508,168
	  	Methods and reagents for the detection of herpes simplex virus, treponema pallidum and haemophilus ducreyi
		
	 USP 5,543,296
	  	Detection of carcinoma metastases by nucleic acid amplification
		
	 USP 5,550,039
	  	Oligonucleotide primers for HLA Class I B locus DNA typing (kit claims excluded)
		
	 USP 5,561,058
	  	Methods for coupled high temperatures reverse transcription and polymerase chain reactions
		
	 USP 5,565,339
	  	Compositions and methods for inhibiting dimerization of primers during storage of polymerase chain reaction reagents
		
	 USP 5,567,809
	  	Methods and reagents for HLA DR beta DNA typing
		
	 USP 5,571,673
	  	Methods for in-solution quenching of fluorescently labeled olignucleotide probes
		
	 USP 5,573,906
	  	Detection of nucleic acids using a hairpin forming oligonucleotide primer and an energy transfer detection system (kit claims excluded)
		
	 USP 5,604,099
	  	Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids (kit claims excluded)
		
	 USP 5,614,388
	  	PCR primers for detection of legionella species and methods for controlling visual intensity hybridization assays
		
	 USP 5,618,703
	  	Unconventional nucleotide substitution in temperature selective rt-PCR (reverse-transcription PCR)
		
	 USP 5,620,847
	  	Methods and reagents for detection of bacteria in cerebrospinal fluid
		
	 USP 5,635,348
	  	Method and probes for identifying bacteria found in blood
		
	 USP 5,643,723
	  	Detection of a genetic locus encoding resistance to rifampin in mycobacterial cultures and in clinical specimens
		
	 USP 5,643,724
	  	Methods and reagents for glycophorin A typing
		
	 USP 5,665,548
	  	Characterization and detection of sequences associated with autoimmune diseases
		
	 USP 5,677,152
	  	Amplification using a reversibly inactivated thermostable enzyme (method and reaction mixture claims only)
		
	 USP 5,693,517
	  	Reagents and methods for coupled high temperature reverse transcription and polymerase chain reactions

 ATTACHMENT 1 

Licensed Technology 
 Page 2 of 3 

 

			
		
	 USP 5,766,888
	  	Detection of carcinoma metastases by nucleic acid amplification
		
	 USP 5,773,258
	  	Nuclease acid amplification using a reversibly inactivated thermostable enzyme (method claims only)
		
	 USP 5,804,375
	  	Reaction mixtures for detection of target nucleic acids (kit claims excluded)
		
	 USP 5,912,117
	  	Method for diagnosis of lyme disease
		
	 USP 5,994,056
	  	Homogeneous methods for nucleic acid amplification and detection
		
	 USP 6,127,155
	  	Stabilized thermostable nucleic acid polymerase compositions containing non-ionic polymeric detergents
		
	 USP 6,171,785
	  	Methods and devices for homogeneous nucleic acid amplification and detection
		
	 USP 6,174,670
	  	Monitoring amplification of DNA during PCR
		
	 USP 6,194,561
	  	Characterization and detection of sequences associated with autoimmune diseases
		
	 USP 6,569,627
	  	Monitoring hybridization during PCR using SYBRTM Green I
		
	 USP 6,664,046
	  	Quantification of hTERT mRNA expression
		
	 USP 6,656,691
	  	TCF-1 nucleotide sequence variation
		
	 USP 6,933,119
	  	Methods and compositions for the detection and treatment of multiple sclerosis

  

									
	EXPRESSION DIAGNOSTICS	 		 	Accepted and Agreed
		 		 		 	ROCHE MOLECULAR SYSTEMS, INC.
					
	By:	 	 /s/ Vikram Jog
	 		 	By:	 	 /s/ Melinda Griffith

	Name:	 	Vikram Jog	 		 	Name:	 	Melinda Griffith
	Title:	 	CFO	 		 	Title:	 	Senior VP & General Counsel
	Date:	 	December 21, 2006	 		 	Date:	 	January 8, 2007

 FIRST AMENDMENT TO PCR PATENT LICENSE AGREEMENT 

This Amendment (“Amendment”), effective as of , 2007 is made by and between Expression Diagnostics, Inc.
(“ED”), a Delaware corporation having its registered office at 3260 Bayshore Blvd., Brisbane, CA 94005, and Roche Molecular Systems, Inc., a Delaware corporation having its registered office at 4300 Hacienda Drive, Pleasanton,
California 94588, (“RMS”). 
 WHEREAS, the parties entered into the PCR Patent License Agreement dated November 16,
2004 by and between ED and RMS (the “Agreement”); 
 WHEREAS, ED and RMS desire to make certain changes to the
Agreement to allow ED to sell securities on public markets as specified below; and 
 NOW THEREFORE, in consideration of the covenants and
conditions contained herein, the parties agree as follows: 
  

	 	1.	Section 7.3 of the Agreement is hereby amended and restated in its entirety to read as follows: 

“Termination for Change of Control, Etc. RMS shall have the right to terminate this Agreement and the license rights granted
herein immediately upon written notice to ED upon any material change in the ownership or control of ED or of its assets or in the event ED breaches the provisions of Section 10 below; provided that RMS shall not have the right to terminate
this Agreement and the license rights granted herein based upon (a) any consolidation, business combination, or merger effected exclusively to change the domicile or name of ED, (b) any consolidation, business combination, or merger in
which the holders of capital stock of ED immediately prior to such consolidation, business combination, or merger continue to hold at least 50% of the voting power of the capital stock of ED or the surviving or acquiring entity following the
transaction and (c) any issuance of capital stock of ED, whether by private or public offering by ED, conversion of debt, or the exercise of warrants in a transaction or series of related transactions whose primary purpose is to raise capital
for ED.” 
  

	 	2.	Section 10 of the Agreement is hereby amended by adding the following sentence to the end of Section 10: 

“Notwithstanding anything to the contrary herein, ED shall not be in breach of this Section 10 based upon (a) any consolidation,
business combination, or merger effected exclusively to change the domicile or name of ED, (b) any consolidation, business combination, or merger in which the holders of capital stock of ED immediately prior to such consolidation, business
combination, or merger continue to hold at least 

  
 1 

 
50% of the voting power of the capital stock of ED or the surviving or acquiring entity following the transaction and (c) any issuance of capital stock of ED, whether by private or public
offering by ED, conversion of debt, or the exercise of warrants in a transaction or series of related transactions whose primary purpose is to raise capital for ED.” 

3. Defined terms shall have the meaning assigned to them in the Agreement. Except as expressly and unambiguously stated herein, no other
changes are made to the Agreement. All other terms and conditions of the Agreement shall remain in full force and effect. 
 IN WITNESS WHEREOF, the parties
have caused this Amendment to be executed by their duly authorized representatives. 
  

			
	EXPRESSION DIAGNOSTICS, INC.	  	ROCHE MOLECULAR SYSTEMS, INC.
		
	 /s/ Vikram Jog

Signature
	  	 /s/ Henry A. Erlich

Signature

		
	 VIKRAM JOG

Name
	  	 HENRY A. ERLICH

Name

		
	 CFO

Title
	  	 VP, DISCOVERY RESEARCH

Title

		
	 7/9/07

Date
	  	 JUNE 28, 07

Date

  

			
	Apprv’d As to Form
RMS LAW DEPT.
		
	By:	 	 /s/ [ILLEGIBLE]

  
 2 

 ***Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
  

 October 10, 2008 

Jay Moyes 
 Chief Financial Officer 

Expression Diagnostics 
 3760 Bay Shore Boulevard 

Brisbane, C 94005 
  

	Re:	Agreement effective November 16, 2004 between Roche Molecular Systems, Inc. (“RMS”) and Expression Diagnostics (“ED”) for use of the Polymerase Chain Reaction (PCR) technology in human in
vitro diagnostic services (“the Agreement”) 

 Dear Jay, 

Pursuant to your letter dated September 5, 2008 describing ED’s AlloMap HTx test, a royalty-bearing fraction of [***]% of the test charge is hereby
set effective September 10, 2008. We understand that the remaining [***]% of the charge covers ED’s proprietary algorithm and related interpretation. 

Enclosed is a updated Attachment I to the referenced Agreement which reflects AlloMap HTx as a Combination Service. We recommend that you insert this
revised Attachment I into your original Agreement. 
 Kind regards, 

ROCHE MOLECULAR SYSTEMS, INC. 

/s/ Donna Donohue 
 Donna Donohue 

Licensing Manager 
 dd 

Enclosure(s) 
  

							
	 Roche Molecular
 Systems,
Inc.
	 	 4300 Hacienda Drive
 PO Box 9002

Pleasanton, CA 94566-0900
 USA
	 		 	

  

 ***Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
  

 ATTACHMENT I 

COMBINATION SERVICES 
  

			
	 Licensed Services
	 	 Percent of Net Service Revenues

for Combination Services which

is Attributable to Licensed Services

		
	 AlloMap HTx
	 	                        [***]

 Effective 09/10/08Prepared by R.R. Donnelley Financial -- EX-10.15

 Exhibit 10.15 

***Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the
Securities and Exchange Commission. 
 DATED JUNE 20, 2013 

 

	 	(1)	XDx, Inc. 

  

	 	(2)	Diaxonhit 

  

 
 DISTRIBUTION
AND LICENSING 
 AGREEMENT 
  

 

 TABLE OF CONTENTS 

 

							
	 	  	Page	 
		
	 1.DEFINITIONS AND INTERPRETATION
	  	 	1	  
		
	 2.APPOINTMENT AND GRANT
	  	 	8	  
		
	 3.INITIAL PAYMENT AND MILESTONES
	  	 	10	  
		
	 4.CE MARKING
	  	 	13	  
		
	 5.TESTING LABORATORY AND NETWORK
	  	 	13	  
		
	 6.COMMERCIALISATION AND DIAXONHIT OBLIGATIONS
	  	 	15	  
		
	 7.FORECAST SALES
	  	 	16	  
		
	 8.TRADEMARK
	  	 	17	  
		
	 9.SUPPLY OF PRODUCTS
	  	 	18	  
		
	 10.DELIVERY, TITLE AND RISK OF LOSS
	  	 	18	  
		
	 11.SAMPLE PRODUCTS
	  	 	18	  
		
	 12.XDX OBLIGATIONS
	  	 	19	  
		
	 13.PURCHASE PRICE AND PAYMENT
	  	 	19	  
		
	 14.NON CONFORMING PRODUCT
	  	 	20	  
		
	 15.PRODUCT RECALL
	  	 	21	  
		
	 16.TRADEMARK AND PATENT INFRINGEMENT
	  	 	22	  
		
	 17.REPRESENTATIONS AND WARRANTIES
	  	 	23	  
		
	 18.COMPLIANCE/ANTI-CORRUPTION LAWS/EXPORT CONTROL
	  	 	24	  
		
	 19.INDEMNIFICATION
	  	 	24	  
		
	 20.INDEMNITY ACTIONS
	  	 	25	  
		
	 21.NO IMPLIED WARRANTIES
	  	 	26	  
		
	 22.LIMITATION OF LIABILITY
	  	 	27	  
		
	 23.CONFIDENTIALITY
	  	 	28	  
		
	 24.TERM AND TERMINATION
	  	 	29	  
		
	 25.CONSEQUENCES OF TERMINATION
	  	 	30	  
		
	 26.ASSIGNMENT
	  	 	31	  
		
	 27.GENERAL PROVISIONS
	  	 	31	  
			
	 Schedule 1
	  	Patent and/or Patent Applications	  	 	37	  
			
	 Schedule 2
	  	Part A – Products and Purchase Prices	  	 	38	  
			
		  	Part B – Specifications	  	 	38	  
			
	 Schedule 3
	  	Trademarks	  	 	40	  
			
	 Schedule 4
	  	Issue of DHT Shares	  	 	41	  
			
	 Schedule 5
	  	Sample Products	  	 	48	  
			
	 Schedule 6
	  	Governance of Collaboration Committee	  	 	49	  
			
	 Schedule 7
	  	Designated Products	  	 	50	  

 ***Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
  

					
	DATED	  	June 20, 2013	  	

 PARTIES 
  

	(1)	XDx, Inc., a company incorporated in Delaware, United States with its registered address at 3260 Bayshore Boulevard, Brisbane, California 94005, United States (“XDx”); and 

 

	(2)	Diaxonhit, a “société anonyme” (stock corporation) incorporated in France under no. 414 488 171 RCS Paris with its registered address at 63-65 Blvd Masséna, 75013 Paris,
France, with ordinary shares listed on the NYSE Alternext market in Paris (“Diaxonhit”). 

 RECITALS 

 

	(A)	XDx owns exclusive rights to manufacture and commercialise the AlloMap® Molecular Expression Test and related products and consumables. 

 

	(B)	XDx and Diaxonhit wish to enter into an agreement to appoint Diaxonhit to Promote and Distribute the Product in the Territory on an exclusive basis, all on the terms of this Agreement. 

 

	(C)	XDx and Diaxonhit wish to appoint a certified third party laboratory to perform the Test in the Territory, to be supervised by Diaxonhit. 

OPERATIVE PROVISIONS 
 NOW THEREFORE, in consideration of
the mutual covenants contained in this Agreement and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows: 

 

	1.	DEFINITIONS AND INTERPRETATION 

  

	1.1	Unless otherwise specifically provided in this Agreement, the following terms shall have the following meanings: 

  

	  1.1.1	“Additional Territories” means [***] and [***]. 

  

	  1.1.2	“Affiliate” means, with respect to a Person, any Person that Controls, is Controlled by or is under common Control with such Person from time to time. 

 

	  1.1.3	“Agreement” means this distribution and licensing agreement including all Schedules and Exhibits. 

  

	  1.1.4	“Anti-Corruption Laws” means the US Foreign Corrupt Practices Act of 1977, the UK Bribery Act 2010 and any other Applicable Laws and Regulations for the prevention of fraud, corruption, racketeering,
money laundering and/or terrorism. 

  

	  1.1.5	“Applicable Laws and Regulations” means all national, supra-national, federal, state, local, foreign or provincial laws, rules, regulations, including case law, as well any guidance, guidelines and
requirements of any Regulatory Authorities and any industry codes of practice in effect from time to time applicable to the activities performed under this Agreement and the handling of the Products in any part of the Territory, including but not
limited to the Directive. 

  
 1 

	  1.1.6	“CE Mark” means the CE mark indicating that a Designated Product (including the Test) is in conformity with the Directive or any legislation implementing, superceding or amending the Directive.

  

	  1.1.7	“Change in Control” with respect to a Party means any transaction where a person who did not previously Control that Party obtains Control of it as a result of such transaction, or where a person who
previously Controlled that Party prior to the closing of such transaction ceases to do so as a result of such transaction. 

  

	  1.1.8	“Competing Product” means any testing process or related products or consumables that are intended to identify or analyse the same or substantially the same cardiac disease, condition or patient
population as the Test. 

  

	  1.1.9	“Confidential Information” has the meaning given in clause 23. 

  

	  1.1.10	“Control” means (a) to possess, directly or indirectly, the power to direct the management or policies of a Person, whether through ownership of voting securities or by contract relating to voting
rights or corporate governance or otherwise; or (b) to own, directly or indirectly, fifty percent (50%) or more of the outstanding voting securities or other ownership interest of such Person and “Controlled” shall have a
corresponding meaning. 

  

	  1.1.11	“Deductions” means the following, to the extent actually paid by Diaxonhit, included in the Gross Sales and allocated to the Product, calculated in accordance with IFRS: 

 

	 	(a)	the total of the Purchase Price paid to XDx; 

  

	 	(b)	quantity and other relevant trade discounts; 

  

	 	(c)	returns; 

  

	 	(d)	rebates in connection with the sale of the relevant Products; 

  

	 	(e)	Indirect Taxes; and 

  

	 	(g)	In the event Diaxonhit engages a Testing Lab for the performance or operation of Tests and as between Diaxonhit and such Testing Lab, Diaxonhit (or an Affiliate or Sales Agent of Diaxonhit) is the party invoicing
end-user hospitals for such Tests and such invoiced amount is included in the Gross Sales, fees paid by Diaxonhit to such Testing Lab for the performance of such Tests. 

 

	  1.1.12	“Designated Products” shall mean the Products that require a CE Mark and listed on Schedule 7. 

  

	  1.1.13	“Designee” means such Person as shall be designated by XDx to manufacture and deliver the Product from time to time. 

 

	  1.1.14	“DHT Shares” means the ordinary shares to be issued by Diaxonhit to XDx pursuant to clauses 3.1 and 3.2 and Schedule 4. 

 

	  1.1.15	“Directive” means the In Vitro Diagnostic Medical Devices Directive (98/79/EC) and/or any legislation implementing, superceding or amending the Directive). 

 

	  1.1.16	“Distribution” with respect to each Product, means the action of Promoting, selling, offering to sell, importing, receiving, warehousing, storing, handling, picking, packing and transportation of the
Products and all related activities and “Distribute” shall have a corresponding meaning. 

  
 2 

 ***Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
  
  

	  1.1.17	“Due Date” has the meaning given in clause 27.9. 

  

	  1.1.18	“Effective Date” means the date of execution of this Agreement. 

  

	  1.1.19	“Exhibit” means an Exhibit to this Agreement. 

  

	  1.1.20	“Export Regulations” has the meaning given in clause 18.3. 

  

	  1.1.21	“Force Majeure” has the meaning given in clause 27.5. 

  

	  1.1.22	“Force Majeure Party” means a Party hindered, prevented or delayed in its performance of this Agreement by an event of Force Majeure. 

 

	  1.1.23	“Group” means a Party and its Affiliates. 

  

	  1.1.24	“Gross Sales” means, in respect of any period, the aggregate gross amount received by Diaxonhit or any of its Affiliates or Sales Agents for all arm’s length sales of the Products and the
performance or operation of Tests during such period. For the avoidance of doubt: 

  

	 	(a)	sales of Products to a Testing Lab shall be included in the calculation of Gross Sales; 

  

	 	(b)	sales of Products to Sub-Distributors shall be included in the calculation of Gross Sales; 

  

	 	(c)	sales to Affiliates or Sales Agents shall not be included in the calculation of Gross Sales; 

  

	 	(d)	subsequent sales by such Affiliates or Sales Agents shall be included in the calculation of Gross Sales; and 

  

	 	(e)	in the event Diaxonhit engages a Testing Lab for the performance or operation of Tests and as between Diaxonhit and such Testing Lab, Diaxonhit is the party invoicing end-user hospitals for such Test, the invoiced
amount for such Tests shall be included in the calculation of Gross Sales, provided that the amount set forth in this subsection (e) may be subject to the Deduction set forth in clause 1.1.11(g). 

 

	 	(f)	in the event Diaxonhit engages a Testing Lab for the performance or operation of Tests and as between Diaxonhit and such Testing Lab, the Testing Lab is the party invoicing end-user hospitals for such Test, the fees
received by such Testing Lab from end-user hospitals for the performance or operation of such Tests shall not be included in the calculation of Gross Sales, but any amount paid by the Testing Lab to Diaxonhit therefore shall be included in the Gross
Sales. 

  

	  1.1.25	Gross Sales for each AlloMap plate sold shall be calculated as (a) the number of Tests performed using each AlloMap plate, multiplied by (b) the Gross Sales actually invoiced for each Test, provided that, if
the number of Tests performed using any AlloMap plate is fewer than the Minimum Number (as defined below), the Gross Sales for such AlloMap Plate shall be calculated as (c) the Minimum Number, multiplied by (d) the Gross Sales actually
invoiced for each Test actually performed. “Minimum Number” means [***] for the Tests performed during the first Sales Year and [***] for the second Sales Year and thereafter. 

  
 3 

	  1.1.26	“Indemnification Claim Notice” has the meaning given in clause 20.1. 

  

	  1.1.27	“Indemnified Party” means a Person seeking to recover Loss under an indemnity in this Agreement. 

  

	  1.1.28	“Indemnifying Party” means the Party from whom recovery of Loss is sought under an indemnity in this Agreement. 

  

	  1.1.29	“Indemnitee” has the meaning given in clause 20.1. 

  

	  1.1.30	“Independent Expert” has the meaning defined in clause 14.2. 

  

	  1.1.31	“Indirect Taxes” means value added taxes, sales taxes, consumption taxes and other similar taxes, but excluding any income taxes. 

 

	  1.1.32	“Information” means all information and know-how relating to the Product that is controlled by and freely available to XDx and is reasonably required by Diaxonhit to enable Diaxonhit to perform its
obligations under this Agreement and maximise sales of the Products, including clinical information, storage specifications, information relating to the characteristics of the Product. 

 

	  1.1.33	“Insolvency Event” means any of the following events: where a Party ceases to do business, becomes unable to pay its debts when they fall due, or is deemed to be insolvent, has a receiver, manager,
administrator, administrative receiver or similar officer appointed in respect of it or the whole or any part of its assets or business, any composition or arrangement is made with any one or more classes of its creditors, takes or suffers any
similar action in consequence of debt, an order or resolution is made or passed for its dissolution or liquidation (other than for the purpose of solvent amalgamation or reconstruction), enters into liquidation whether compulsorily or voluntarily or
any analogous or comparable event takes place in any jurisdiction. 

  

	  1.1.34	“Launch Date” means the date of Diaxonhit’s first commercial sale of the Product in any part of the Territory to any Person other than an Affiliate, Sales Agent or Sub-Distributor of Diaxonhit for
end use or consumption after all the necessary Regulatory Approvals for such sale have been granted. 

  

	  1.1.35	“Loss” means any and all liabilities, claims, demands, causes of action, damages, loss and expenses, including interest, penalties, reasonable professional fees and reasonable lawyers’ fees on a
solicitor client basis together with disbursements. 

  

	  1.1.36	“Material Anti-Corruption Law Violation” means a violation of an Anti-Corruption Law which would if it were publicly known, in the reasonable view of the non-violating Party, have a material adverse
effect on the Party that has perpetrated such violation or on the reputation of the non-violating Party as a result of its relationship with the Party that has perpetrated the violation. 

 

	  1.1.37	“Net Sales” means with respect to any period Gross Sales minus Deductions. 

  

	  1.1.38	“Net Sales Price” with respect to any period, means (a) Net Sales divided by (b) the aggregate number of Units sold in such arm’s length sales. 

For purposes of computing the Net Sales Price for any month (or any other payment under this Agreement, if applicable), any amounts invoiced in
a currency other than Euros shall be converted into Euros by applying the closing midpoint currency rates as of the last business 

  
 4 

 
day of such calendar month, as published in the Financial Times of London for such currency; provided that in the event the closing midpoint currency rate of any such currency is not published in
the Financial Times of London as of the last business days of a particular calendar month, the closing midpoint currency rate of the immediately preceding date on which such rate is published by the Financial Times of London shall be used. If the
Financial Times of London ceases operations or otherwise ceases reporting any financial information necessary to make such calculation as required by this Agreement, “Financial Times of London” as used herein shall mean such other database
or reporting system reporting midpoint currency rates most closely approximating the Financial Times of London. 
  

	  1.1.39	“Parties” means XDx and Diaxonhit and “Party” shall mean either of XDx or Diaxonhit. 

  

	  1.1.40	“Patents” means the patents and/or patent applications set out in Schedule 1 together with any and all continuations, divisions, renewals, re-issues, amendments or extensions, including supplementary
protection certificates of such patents and/or patent applications, in the Territory. 

  

	  1.1.41	“Person” means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust,
incorporated association, joint venture or similar entity or organization, including a Regulatory Authority. 

  

	  1.1.42	“Products” means the Products listed in Schedule 2 to be used and marketed by Diaxonhit in respect of the Test in the Territory under the Trademark, as more particularly described in the Specification.
The term “Product” shall, where the context permits, also include Sample Products. 

  

	  1.1.43	“Promote” means any activity to market, promote or communicate the sale, supply or use of the Product, including advertising, discussing the Product with doctors, patients and other potential customers,
making announcements, arranging and attending medical/scientific meetings and invitations or sponsorship to attend medical/scientific meetings and any other activities normally undertaken by a pharmaceutical company’s sales force to implement
marketing plans and strategies aimed at encouraging the appropriate use of a particular prescription or other pharmaceutical product, provided that “Promote” shall not include any actions undertaken in connection with obtaining the
Regulatory Approvals and “Promotion”, “Promoting” and other connected terms shall have a corresponding meaning. 

  

	  1.1.44	“Promotional Code” means the standards set forth in the European Diagnostic Manufacturers Association Code of Ethics, as applicable. 

 

	  1.1.45	“Promotional Materials” means all materials used by Diaxonhit to Promote the Product, including advertisements, brochures and other written material, audio and video material, computer based and any
online material, display panels, gifts, press/media communications and training and briefing materials for sales representatives. 

  

	  1.1.46	“Purchase Price” means the price paid by Diaxonhit for the Products set out in Schedule 2. 

  

	  1.1.47	“Quarter” means one of the following periods in each Sales Year: 

  

	 	(a)	1 January to 31 March; 

  
 5 

 ***Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
  

	 	(b)	1 April to 30 June; 

  

	 	(c)	1 July to 30 September; and 

  

	 	(d)	1 October to 31 December; 

 and “Quarterly” shall be construed
accordingly. 
  

	  1.1.48	“Regulatory Approvals” means all permissions, authorisations and licences that are necessary for the use, possession, Promotion or Distribution of the Products or the performance of this Agreement in
the Territory or any part of it, including those required by Applicable Laws and Regulations and pricing and reimbursement approval, if applicable. 

  

	  1.1.49	“Regulatory Authority” means any court or government body, whether national, supra-national, federal, state, local, foreign or provincial, including any political subdivision thereof, including any
department, commission, board, bureau, agency, or other regulatory or administrative governmental authority or instrumentality, and further including any quasi-governmental person or entity exercising the functions of any of these.

  

	  1.1.50	“Relevant Facilities” means laboratories, facilities, warehouses and any other locations used by Diaxonhit, its Sales Agents and Sub-Distributors in connection with the Distribution of the Products in
the Territory and the performance of Diaxonhit’s obligations under this Agreement and all records pertaining thereto. 

  

	  1.1.51	“Royalty” means [***]% of the Net Sales Price. 

  

	  1.1.52	“Sales Agent” means an agent appointed by Diaxonhit to act on its behalf with respect to the sale of Products and Tests in the Territory. 

 

	  1.1.53	“Sales Year” means any calendar year during the Term, provided that the first Sales Year shall commence on the Launch Date and end on 31 December in the same calendar year and the last Sales Year
shall commence on 1 January and end on the date of expiry or termination of this Agreement. 

  

	  1.1.54	“Sample Product” means samples of the Products that are not for commercial sale but for promotional purposes or internal use only. The Sample Product shall be suitable for supply to customers in the
Territory.  

  

	  1.1.55	“Schedule” means a schedule to this Agreement. 

  

	  1.1.56	“Specification” means the specification set out in Part B of Schedule 2 as may be amended from time to time by XDx, subject to obtaining any necessary Regulatory Approvals. 

 

	  1.1.57	“Sub-Contract” means any contract between Diaxonhit or an Affiliate and a third party pursuant to which Diaxonhit delegates its obligations under this Agreement. 

 

	  1.1.58	“Sub-Contractor” means a Person with whom Diaxonhit or an Affiliate enters into a Sub-Contract or such Person’s employees, servants or agents. 

 

	  1.1.59	“Sub-Distributor” means a Person whom Diaxonhit or an Affiliate appoints to act as a sub-distributor in any part of the Territory. 

 

	  1.1.60	“Term” means the period beginning on the Effective Date and continuing until the earlier of the date upon which this Agreement expires by its terms or is terminated in accordance with clause 24.

  
 6 

	  1.1.61	“Territory” means the European Economic Area. 

  

	  1.1.62	“Test” means the AlloMap® Molecular Expression test as set out in the Specification and “Testing” shall be construed accordingly.

  

	  1.1.63	“Testing Lab” means any Testing Lab, including the “Dausset Lab”, as such terms are defined in clause 5.1, to be appointed by the Parties in the Territory, pursuant to a specific agreement for
the operation of the Test. 

  

	  1.1.64	“Third Party Claim” means any claim of a third party against a Party arising from the other Party’s activities under this Agreement. 

 

	  1.1.65	“Trademark” means the AlloMap® trademark set forth in Schedule 3 owned by XDx or one of its Affiliates, which Diaxonhit shall use as the trade
name of the Product. 

  

	  1.1.66	“Unit” means any Product. 

  

	  1.1.67	“Working Day” in relation to any obligation means a day other than a Saturday, Sunday or public holiday in the relevant place of performance of that obligation. 

 

	1.2	Unless the context requires otherwise: 

  

	 	(A)	references to this Agreement include the Schedules and Exhibits and are to this Agreement as it is from time to time amended; 

  

	 	(B)	headings are for convenience only and shall not affect interpretation; 

  

	 	(C)	references to clauses are to clauses in the main body of this Agreement and references to paragraphs are to paragraphs of the Schedules and Exhibits, references to paragraphs made in a Schedule or an Exhibit are, unless
otherwise stated in that Schedule or Exhibit, references to paragraphs of that Schedule or Exhibit; 

  

	 	(D)	references to the singular include the plural and vice versa, and references to one gender include all genders; 

  

	 	(E)	any phrase introduced by the expressions “including”, “include”, “in particular” or any similar expression shall be construed as illustrative and shall not limit the
sense of the words preceding those terms; 

  

	 	(F)	reference to any law: 

  

	 	(1)	shall be deemed to include any by-laws, licences, statutory instruments, rules, regulations, orders, notices, directions, consents or permissions made under that law; and 

 

	 	(2)	shall be construed as referring to any law which replaces, re-enacts, amends or consolidates such law (with or without modification) at any time; 

 

	 	(G)	any reference to an English legal expression for any action, remedy, method of judicial proceeding, legal document, legal status, court, official or any legal concept or thing shall, in respect of any jurisdiction other
than England, be deemed to include a reference to what most nearly approximates in that jurisdiction to the English legal expression; and 

  
 7 

	 	(H)	references to “writing” or “written” include any modes of reproducing words in a legible and non-transitory form but do not include writing on the screen of a visual display unit or
other similar device. 

  

	1.3	In the case of conflict or ambiguity between the provisions contained in the body of this Agreement, any provision contained in any Schedule or Exhibit or any documents attached to or referred to in this Agreement, the
order of priority shall be as follows: 

  

	 	(A)	this Agreement (excluding its Schedules and Exhibits); 

  

	 	(B)	the Schedules and Exhibits; and 

  

	 	(C)	documents referred to in this Agreement. 

  

	2.	APPOINTMENT AND GRANT 

  

	2.1	Subject to the terms and conditions of this Agreement, XDx hereby appoints Diaxonhit for the Term, on an exclusive basis, to Promote and Distribute the Product in the Territory and Diaxonhit hereby accepts such
appointment. 

  

	2.2	Subject to the terms and conditions of this Agreement, XDx hereby grants to Diaxonhit an exclusive license for the Term to Promote and Distribute the Product in the Territory in accordance with this Agreement under the
Trademark and using the Patents and the Information, together with the right to grant sub-licenses, subcontract and sub-distribute its rights in accordance with this Agreement. Diaxonhit may grant sublicenses only in accordance with clause 2.12 or
with the prior written consent of XDx. 

  

	2.3	XDx shall have no right to Promote, Distribute, offer for sale and/or sell the Product or Competing Products in the Territory in any manner, including under the Trademark or using the Patents, and to grant to any Person
or Persons the right and license to do any or all of the foregoing. In the event XDx undergoes a Change of Control, this Section 2.3 shall not apply to any independent products or tests developed and/or commercialized by any acquiror or merger
partner of XDx. 

  

	2.4	Diaxonhit shall not and shall procure that its Affiliates, Sales Agents and Sub-Distributors will not Distribute or Promote Product directly or indirectly to any Person in any country that is outside of the Territory.

  

	2.5	Diaxonhit undertakes, subject to termination or expiry of this Agreement, that it shall purchase its and its Affiliates’ and Sales Agents entire requirement of the Products exclusively from XDx or the Designee
during the Term of this Agreement. 

  

	2.6	Diaxonhit undertakes, subject to termination or expiry of this Agreement, that, for the Term and for a period of no longer than two (2) years from the expiry or termination date hereof it shall not, and shall
ensure that its Affiliates shall not, be engaged or interested directly or indirectly in the development, manufacture, formulation, packaging, promotion, sale, or distribution in the Territory of any Competing Product. In the event Diaxonhit
undergoes a Change of Control, this Section 2.6 shall not apply to any independent products or tests developed and/or commercialized by any acquiror or merger partner of Diaxonhit. 

 

	2.7	Diaxonhit shall: 

  

	 	(A)	keep full and proper books of account and records showing clearly all enquiries, quotations, transactions and proceedings relating to Products; 

  
 8 

	 	(B)	keep all stocks of Products which it holds in conditions which accord with XDx’s Specifications; 

  

	 	(C)	ensure it does not give any warranties concerning the Product other than those specifically provided by XDx, or Promote the Product for use other than those uses specifically included within the Regulatory Approvals;
and 

  

	 	(D)	not make any claims or encourage any use of the Product which has not been approved by XDx. 

  

	2.8	Diaxonhit shall not: 

  

	 	(A)	represent itself as an agent of XDx for any purpose; 

  

	 	(B)	pledge XDx’s credit; 

  

	 	(C)	give any warranty or make any representation on XDx’s behalf; 

  

	 	(D)	commit or purport to commit XDx to any contract or otherwise incur any liability on behalf of XDx; 

  

	 	(E)	make any promises, warranties or guarantees with reference to the Products beyond those contained in the current Promotional Material approved by XDx without XDx’s prior written consent; 

 

	 	(F)	make any material changes to Diaxonhit’s Promotional Code and promotional activities as in place on the Effective Date; or 

  

	 	(G)	undertake any activity with respect to the Product in violation of the Promotional Code. 

  

	2.9	Diaxonhit shall comply with all Applicable Laws and Regulations and each Regulatory Approval in respect of its performance of this Agreement. 

 

	2.10	If, at any time, XDx wishes to launch, or grant a third party a licence to launch the Product or the Test in any of the Additional Territories then it shall first notify Diaxonhit in writing. XDx and Diaxonhit shall
meet and conduct negotiations in good faith with a view to agreeing to amend this Agreement to include such an Additional Territory as part of the Territory. XDx shall not, and shall ensure that its Affiliates shall not, conduct any negotiations
with any third party with respect to such licence or launch of the Products in the Additional Territories for a period of four (4) months following the service of such notice. 

 

	2.11	Other than as expressly provided in this Agreement, nothing in this Agreement shall be construed to confer any rights upon either Party by implication, estoppels, or otherwise as to any technology or patent rights of a
Party. 

  

	2.12	Sub-Contractors, Sales Agents and Sub-Distributors 

  

	 	(A)	Any of Diaxonhit’s rights and obligations under this Agreement may be exercised or performed by any of its Affiliates and Diaxonhit may sublicence any of the rights granted to it by XDx to such an Affiliates,
subject always to clause 2.12(F) 

  

	 	(B)	Diaxonhit shall be permitted to sub-contract its obligations under this Agreement as it sees fit, subject to the prior written approval of XDx, which approval shall not be unreasonably withheld or delayed. Any
Sub-Contractor shall not further subcontract such obligations. 

  
 9 

 ***Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
  

	 	(C)	Diaxonhit shall be permitted to appoint Sales Agents to act on its behalf with respect to the Distribution and Promotion of the Test and the Products throughout the Territory, except that Diaxonhit shall not appoint
Sales Agents in: (i) [***] and [***]; or (ii) any other country or region where Diaxonhit establishes direct sales operations after the Effective Date, provided that Diaxonhit shall have the right to transition the sales responsibilities
from any Sales Agents engaged by it prior to such establishment within a reasonable period of time, unless both parties agree that such Sales Agents should remain engaged. 

 

	 	(D)	Diaxonhit shall be permitted to appoint Sub-Distributors to act as distributors or resellers of the Products and the Test. 

  

	 	(E)	All Sales Agents, Sub-Distributors and Sub-Contractors appointed by Diaxonhit shall be appointed on terms which oblige such Sales Agents and Distributors to ensure that: 

 

	 	(1)	they store, Distribute and Promote the Tests and the Products in accordance with Diaxonhit’s obligations under this Agreement; and 

 

	 	(2)	they take all reasonable steps to ensure that their customers, and any Tests requested by their customers, are submitted to the Testing Lab in accordance with the Specifications. 

 

	 	(F)	Diaxonhit shall remain primarily liable for the performance of its Affiliates, Sub-Contractors, Sales Agents and Sub-Distributors. 

  

	 	(G)	A Testing Lab shall not be regarded as a Sub-Contractor for the purposes of this Agreement and terms and conditions governing the engagement of the Testing Lab shall be governed under clause 5. 

 

	3.	INITIAL PAYMENT AND MILESTONES 

  

	3.1	In consideration of the rights granted under this Agreement, Diaxonhit shall pay to XDx the non-creditable Initial Payment comprising the following: 

 

	 	(A)	three hundred and eighty seven thousand five hundred Euros (€387,500) in immediately available funds (“the Initial Cash Payment”) on the Effective Date; and 

 

	 	(B)	three hundred and eighty seven thousand five hundred Euros (€387,500) in DHT Shares (the “Initial Equity Payment”) upon confirmation that the CE Mark is in place that covers the Designated Products
in the European Union (the “CE Approval”). 

  

	3.2	In addition, during the Term, Diaxonhit shall pay XDx the following milestone payments (“Milestone Payments”): 

  

	 	(A)	[***] Euros (€[***]) in immediately available funds and *** Euros (€[***]) in DHT shares (the “Milestone 1 Equity Payment”) at the end of first 12 month period during the Term where the Net
Sales in the Territory exceeds [***] Euros (€[***]) (the “Milestone 1”); 

  
 10 

 ***Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
  

	 	(B)	[***] Euros (€[***]) in immediately available funds and [***] Euros (€[***]) in DHT Shares (the “Milestone 2 Equity Payment”) at the end of first 12 month period during the Term where the Net
Sales in the Territory exceeds [***] Euros (€[***]) (the “Milestone 2”); 

  

	 	(C)	[***] Euros (€[***]) in immediately available funds and [***] Euros (€[***]) in DHT Shares (the “Milestone 3 Equity Payment”) at the end of first 12 month period during the Term where the Net
Sales in the Territory exceeds [***] Euros €[***] (the “Milestone 3”); and 

  

	 	(D)	[***] Euros (€[***]) in immediately available funds and [***] Euros (€[***]) in DHT Shares (the “Milestone 4 Equity Payment”) at the end of the first 12 month period during the Term where the
Net Sales in the Territory exceeds [***] Euros €[***] (the “Milestone 4”). 

  

	3.3	For the avoidance of doubt, as used in Section 3.2 herein, any “12 month period” shall mean a calendar month beginning on the first day of the first month and ending on the last day of the 12th month during such period. 

  

	3.4	In the event two (2) or more Milestone Payments are triggered within the same twelve (12) month period, then both (or all, as applicable) of such Milestone Payments shall be due concurrently.

  

	3.5	Where an amount is to be paid by Diaxonhit in cash or cleared funds under this Agreement, that payment will be made by bank transfer to an account directed by XDx in immediately available funds. 

 

	3.6	Where an amount is to be paid in DHT Shares pursuant to clauses 3.1 and 3.2, the relevant DHT Shares shall be issued to XDx in accordance with Schedule 4 and sales thereof shall be without any restriction, other than
XDx undertakes and agrees that it may sell, on each single day, a maximum total number of DHT Shares not exceeding 25% of the total number of shares of Diaxonhit traded during the relevant day in order to avoid price disturbance in the public market
where DHT Shares are traded. Diaxonhit undertakes to use its best efforts to assist XDx in connection with the sale by XDx of its DHT Shares on the relevant market. 

 

	3.7	For the purpose of this Section 3: 

 (i) XDx shall promptly notify Diaxonhit of the
satisfaction of the CE Approval (the “CE Notification”), in which case Diaxonhit shall: (a) calculate pursuant to Schedule 4 the total number of (i) Warrants (as defined in Schedule 4) exercisable by XDx and
(ii) underlying DHT Shares which may be subscribed by XDx upon exercise of such Warrants, and (b) prepare and provide to XDx a draft exercise form (bulletin d’exercice) for the relevant Warrants (the “Subscription
Form”). 
 (ii) No later than on the 20th Working Day of each Quarter, Diaxonhit shall calculate the total amount of the Net Sales
generated during the preceding four (4) Quarters based on the Royalty Reports (as defined in clause 13.2) for the relevant Quarters and, in case of satisfaction of the Milestone 1, Milestone 2, Milestone 3 and/or Milestone 4 pursuant to clause
3.2 during the relevant Quarters, shall so notify XDx (in each case, a “Milestone Notification”). Diaxonhit shall: (a) calculate pursuant to Schedule 4 and specify in each Milestone Notification: the total number of
(i) Warrants (as defined in Schedule 4) exercisable by XDx and (ii) underlying DHT Shares which may be subscribed by XDx upon exercise of such Warrants, and (b) prepare and attach to each Milestone Notification to be provided to XDx
the applicable draft Subscription Form. 

  
 11 

 XDx shall: (i) upon issuance of the CE Notification or receipt of the Milestone
Notification, as applicable, invoice Diaxonhit for the relevant cash and equity payments due by XDx to Diaxonhit pursuant to clause 3.1 or 3.2, as applicable, and (ii) upon receipt of the Subscription Form, complete, execute and notify to
Diaxonhit the Subscription Form; provided that, as regards the equity payments due by Diaxonhit, should the Total Market Value (as defined below) of the DHT Shares to be issued upon exercise of all Initial Warrants, all M1 Warrants, all M2 Warrants,
all M3 Warrants or all M4 Warrants, as applicable, is inferior to the amount of the Initial Equity Payment, the Milestone 1 Equity Payment, the Milestone 2 Equity Payment, the Milestone 3 Equity Payment or the Milestone 4 Equity Payment, as
applicable, Diaxonhit shall pay in cleared funds to XDx an additional cash amount “F” calculated as follows: 
 F = P – TMV

 where: 
 - “P” is
equal to the amount of the Initial Equity Payment, the Milestone 1 Equity Payment, the Milestone 2 Equity Payment, the Milestone 3 Equity Payment or the Milestone 4 Equity Payment, as applicable, set forth in clause 3.1 or 3.2, as
applicable, 
 - “TMV” or “Total Market Value” means the total market value of all DHT Shares which may be subscribed by
XDx upon exercise of all Initial Warrants, all M1 Warrants, all M2 Warrants all M3 Warrants or all M4 Warrants, as applicable, calculated based on the Market Value (as defined in Schedule 4) as follows: 

TMV = NS x MV 
 where: 

- “NS” is equal to the total number of DHT Shares which may be subscribed by XDx upon exercise of all Initial Warrants, all M1
Warrants, all M2 Warrants all M3 Warrants or all M4 Warrants, as applicable, set forth in the CE Notification or relevant Milestone Notification, as applicable; and 

- “MV” is equal to the Market Value of each DHT Share which may be subscribed by XDx upon exercise of all Initial Warrants, all M1
Warrants, all M2 Warrants all M3 Warrants or all M4 Warrants, as applicable, set forth in the CE Notification or relevant Milestone Notification. 
  

	3.8	The Parties further undertake and agree that, should the Warrants be not issued to XDx pursuant to this Agreement for any reason whatsoever, the Parties shall meet and renegotiate in good faith the amounts and payment
terms of the Initial Equity Payment, the Milestone 1 Equity Payment, the Milestone 2 Equity Payment, the Milestone 3 Equity Payment and the Milestone 4 Equity Payment. 

 

	3.9	The Initial Cash Payment is paid as an advance payment in respect of the Royalty due from Diaxonhit in the first three (3) years following the Launch Date and no further Royalty shall be payable by Diaxonhit during
this period until the total Royalty due exceeds such amount. 

  
 12 

	4.	CE MARKING 

  

	4.1	XDx hereby warrants and confirms that: 

  

	 	(A)	it will obtain the CE Approval within 45 days from the Effective Date and shall maintain the CE Mark and any other Regulatory Approvals for the Test and the Products in the Territory throughout the Term; and

  

	 	(B)	the Test and the Products shall comply with the Directive throughout the Term. 

  

	4.2	XDx shall retain primary accountability and responsibility for the CE Marks covering the Designated Products in the Territory, and shall provide Diaxonhit with full access to all files related to such CE Marks. XDx and
Diaxonhit to share equally all costs for the maintenance of the CE Marks after they are obtained. 

  

	4.3	In the event that the CE Mark is revoked for any of the Designated Products then XDx shall take appropriate steps to ensure that such CE Mark is restored and Diaxonhit shall be have the right to terminate this Agreement
if the CE Mark is not restored within three months of such revocation. 

  

	4.4	Diaxonhit agrees to report promptly to XDx all inquiries made to Diaxonhit by the Regulatory Authorities relating to the Product and to co-operate with XDx to develop an appropriate response to such inquiries.

  

	5.	TESTING LABORATORY AND NETWORK 

  

	5.1	From time to time after the Effective Date, the Parties may engage Testing Lab(s) in the Territory only by mutual written agreement and by entering into Testing Service Agreement(s) as set forth in clause 5.

  

	5.2	As of the Effective Date, Diaxonhit and XDx have selected the Jean Dausset Laboratory at the St. Louis Hospital in Paris (“the Dausset Lab”) as a Testing Lab to perform and support all testing services
using the Products in the Territory. Diaxonhit shall make reasonable efforts to negotiate Product sale agreement(s) with the Dausset Lab covering the provision of services by the Dausset Lab to process Tests and including, as reasonably feasible,
some or all of the provisions outlined in clause 5.7 below (the “Dausset Lab Product Sale Agreements”). Such Dausset Lab Product Sale Agreement(s) shall specifically provide for the right for Diaxonhit to reject or cancel orders
placed by or on behalf of Dausset Lab for Products in any situation where the performance of the Test by the Dausset Lab does not strictly conform to Applicable Laws and Regulations, CE Mark and the Specifications, such prohibition to last for the
entire period during which Test performance is non-conforming. Diaxonhit shall, promptly upon execution hereof, supply XDx with copy of a written commitment and representation from the Dausset Lab to the effect that performance of the Test at the
Dausset Lab will be strictly in accordance with Applicable Laws and Regulations, CE Mark and the Specifications; such commitment and representation shall be reflected in, or incorporated by reference into, the Dausset Lab Product Sale Agreement. In
addition, Diaxonhit shall fully cooperate with XDx and use all remedies available at law or in equity in France to enforce such commitment and representation by the Dausset Lab. 

 

	5.3	Once the Dausset Lab is ready to commence processing Tests, Diaxonhit shall serve written notice on XDx requiring XDx to review and approve the measures in place at the Dausset Lab for the processing of Tests within 15
Working Days of receipt of that written notice. The Parties agree that the Dausset Lab shall not process any Tests on a commercial basis until XDx has provided written approval that such Tests can proceed provided that in the event that XDx has not
approved or rejected the measures at the Dausset Lab within 15 Working Days of receipt of the written notice then it shall be deemed to have provided that approval. 

  
 13 

	5.4	For any other Testing Lab engaged by Diaxonhit after the Effective Date in accordance with clause 5.1, Diaxonhit and XDx will carry out equivalent activities and obligations under clause 5.2 and 5.3. 

 

	5.5	Subject to the provisions herein and those contained in the above-referenced Testing Services Agreement, Diaxonhit shall be responsible for all costs associated with the set-up and ongoing processing of the Test in the
Dausset Lab (and any other “Testing Lab”), including, but not limited to equipment and software purchase and maintenance and the translation of all procedures into French (or such other applicable languages). 

 

	5.6	Once the Dausset Lab has been approved by XDx to perform the Tests pursuant to Section 5.3, Diaxonhit shall supervise the ongoing performance of the Tests and report to XDx periodically in a manner for XDx to
verify Dausset Lab’s strict conformance to Applicable Laws and Regulations, CE Mark and the Specifications, and in the event XDx determines that Dausset Lab is not in conformance, at XDx’s request, Diaxonhit shall reject and/or cancel
orders placed by Dausset Lab for the Products as provided in Section 5.2. XDx shall provide periodic technical support on a reasonable basis, and not to exceed ten man hours per month. 

 

	5.7	Testing Services Agreement 

 The Testing Services Agreement shall, amongst other
provisions, provide as follows: 
  

	 	(A)	The Testing Lab shall perform Tests in accordance with Applicable Laws and Regulations, CE Mark and the Specifications and shall not give or allow any warranty in excess of those approved by XDx; 

 

	 	(B)	The Testing Lab shall be responsible to XDx and Diaxonhit for the performance of the Tests; 

  

	 	(C)	The Testing Lab will purchase Products from Diaxonhit or its Affiliate; 

  

	 	(D)	XDx shall have the right, at its own expense, to review the procedures performed to run the Test at the Testing Lab to verify that the Test is being performed in accordance with the Specifications. Such access shall be:

  

	 	(1)	conducted no sooner than 15 Working Days’ after prior written notice has been given to the Testing Lab; 

  

	 	(2)	provided during ordinary business hours; 

  

	 	(3)	conducted in a manner that is not disruptive to Testing Lab’s operations and which is compliant with; 

  

	 	(a)	Applicable Laws and Regulations; 

  

	 	(b)	Testing Lab’s reasonable requirements, including requirements relating to health and safety and scientific procedures; 

  

	 	(c)	Testing Lab’s own confidentiality procedures and requirements, including any such procedures and requirements relating to confidential information of third parties;, and 

 

	 	(4)	no more frequent than once per Sales Year except for cause. 

  
 14 

 ***Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
  

	 	(E)	If an audit reveals that the Testing Lab is not performing the Test in accordance with the Specifications, the Testing Lab will reimburse XDx the cost of such audit and work in good faith to immediately resolve such
deficiencies as soon as possible but in no event more than 30 days. 

  

	 	(F)	The Testing Lab will agree to achieve efficiency in its utilization of the AlloMap plates so that at least [***] Tests are conducted per AlloMap plate for the first year during which Tests are conducted at such
Testing Lab and at least [***] Tests per AlloMap plate thereafter. 

  

	6.	COMMERCIALISATION AND DIAXONHIT OBLIGATIONS 

  

	6.1	Diaxonhit undertakes at its own cost and risk to use commercially reasonable efforts to launch, Promote and Distribute the Products in the Territory under the Trademark consistent with recognised international
pharmaceutical business practices and in compliance with Specifications and all Applicable Laws and Regulations in place in the Territory and the Promotional Code. 

 

	6.2	Without prejudice to clause 6.1 but subject always to clause 4, Diaxonhit shall begin the Promotion of the Test and the Products in [***] and [***] within [***] of Effective Date, and in [***] and [***] within [***] of
the Effective Date PROVIDED THAT the Collaboration Committee may agree at any time to delay, accelerate or reschedule the promotion of the Products in a country if it is thought to be beneficial to the overall exploitation of the Test and the
Products in the Territory. The Collaboration Committee shall agree a plan for the commencement of promotion of the Test and the Products in other countries within the Territory from time to time, and Diaxonhit will conduct its Promotion activities
consistent with such plan. 

  

	6.3	Diaxonhit shall create and develop, at its sole expense and with the prior written approval by XDx, all Promotional Materials used to Promote the Product. Diaxonhit shall Promote the Product using only Promotional
Materials and conducting only such other activities that comply with the Regulatory Approvals, Specifications, the Promotional Code and any other Applicable Laws and Regulations, and in a manner consistent with recognised international
pharmaceutical business practices, and XDx shall not unreasonably withhold or delay its approval in a manner that would cause Diaxonhit to violate such compliance obligation. 

 

	6.4	XDx shall not have any involvement in Diaxonhit’s pricing policies or customer determination, which activities shall remain solely within the discretion of Diaxonhit. Diaxonhit shall make and record its own sales
of the Product but Diaxonhit will provide regular updates to XDx on such matters during the Collaboration Committee (as defined in clause 6.5 herein) meetings. 

  

	6.5	Without prejudice to clause 6.4, the Parties shall set up a committee (“the Collaboration Committee”) to discuss and agree key promotional and testing elements of the relationship, such Collaboration
Committee to be convened at least once every Quarter by teleconference and in person at least once per year at an agreed location. The Collaboration Committee shall have the powers and shall be conducted in accordance with the procedures set out in
Schedule 6. 

  

	6.6	Subject to clause 12, Diaxonhit shall be solely responsible for training its sales representatives with respect to the Product and for all costs associated with such training. 

 

	6.7	Diaxonhit shall not make any reference in its Promotional Materials, or otherwise in Promoting the Product, to XDx or any of its Affiliates or any trademark without obtaining XDx’s prior written consent, other than
the Trademark (and its company logo, if a trademark) and shall indicate that the Test is performed and marketed under license by XDx. 

  
 15 

 ***Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
  

	6.8	Diaxonhit shall be responsible for : 

  

	 	(A)	Providing customer service and support to customers who have purchased or used the Products or the Test in the Territory; 

  

	 	(B)	conducting discussions with relevant Regulatory Authorities to ensure that the Products and the Test are approved for reimbursement by those authorities; 

 

	 	(C)	ensuring the Dausset Lab (and any other Testing Lab) conforms to all applicable XDx testing specifications and all Applicable Laws and Regulations; 

 

	 	(D)	Training and equipping all collection sites in the Territory to obtain the blood specimens for the Test pursuant to the requisite standards, including supplying them with the Collection and Shipper Kits, approved
centrifuges and arranging for shipment of the blood specimens to the Dausset Lab (or any other Testing Lab) 

  

	7.	FORECAST SALES 

  

	7.1	During each Sales Year set forth below, Diaxonhit shall use commercially reasonable endeavours to achieve Sales of the Product in a quantity not less than the following (“Forecast Sales”):

  

			
	 Sales Years
	  	Forecast Sales
(Number of Tests)
	 1.
	  	[***]
	 2.
	  	[***]
	 3
	  	[***]
	 4
	  	[***]
	 5
	  	[***]

  

	7.2	If Diaxonhit fails to achieve at least [***] percent ([***]%) of the applicable Forecast Sales in a Sales Year, the Collaboration Committee shall formally consider what steps if any that can be taken to improve sales in
the subsequent Sales Year. 

  

	7.3	Subject to clause 7.4,: 

  

	 	(A)	if Diaxonhit fails to achieve at least [***] percent ([***]%) of the applicable Forecast Sales in two consecutive Sales Years following Launch Date, then XDx shall have the right to serve written notice on Diaxonhit to
convert the exclusive rights granted pursuant to clauses 2.1 and 2.2 to non-exclusive rights but it shall have no other remedy in respect of such failure, such notice to be served within 60 days of the end of the second such Sales Year; and

  
 16 

 ***Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
  

	 	(B)	if Diaxonhit fails to achieve at least [***] percent ([***]%) of the applicable Forecast Sales in two consecutive Sales Years following Launch Date, then XDx shall have the right to serve written notice on Diaxonhit to
terminate this Agreement. 

  

	7.4	For the avoidance of doubt, Diaxonhit’s obligations under Sections 7.3 shall be tolled for any period of time during which the CE Mark Approval is suspended for any Designated Product, or if any other regulatory
action prohibits the Products and Tests in the Territory. 

  

	7.5	If authorised clinical trials carried out anywhere in the world produce data that materially affects the validity of the performance of the Test, the Parties shall meet to review the Forecast Sales and the provisions of
clause 7.2 and, if agreed, to amend this Agreement in writing in accordance with clause 27.1. XDx shall keep Diaxonhit promptly and fully informed of the results of said clinical trials, such information to be communicated in writing and by email.

  

	8.	TRADEMARK 

  

	8.1	Diaxonhit shall Promote and Distribute the Product in the Territory only under the Trademark and shall also indicate on all Promotional Materials that the Test is performed and marketed under license by XDx. Diaxonhit
shall not use any other trademark or trade name in connection with the Product, provided, however, that Diaxonhit shall have the right to include its name and company logo on all packaging and other printed material pertaining to the Product.

  

	8.2	Diaxonhit and its Affiliates, Sales Agents and Sub-Distributors shall treat the Trademark properly and in accordance with XDx’s instructions from time to time and not by any act cause or contribute to its
deterioration or adversely affect XDx’s or any of its Affiliates’ rights in the Trademark. 

  

	8.3	XDx and/or its Affiliates shall at all times retain ownership of the entire right, title and interest in and to the Trademark and any label, trade name, trade dress, service mark or device used in connection with the
Product. 

  

	8.4	Diaxonhit acknowledges and agrees that the Trademark shall be and will remain the exclusive property of XDx or its Affiliates. No right, title or interest of any kind in or to the Trademark or any other trademark,
label, trade name, trade dress, service, mark or device is transferred by this Agreement to Diaxonhit or its Affiliates, except the rights granted pursuant to clause 2.2. Diaxonhit agrees that it will not use, except in accordance with this
Agreement, or attempt to register, the Trademark, or any marks similar thereto, in any language or anywhere in the world. Diaxonhit further agrees that it will not take any action that would harm the Trademark or impair the owners’ rights
therein or adopt any trademark that is confusingly similar to or a colourable imitation of the Trademark. Diaxonhit shall ensure that its Affiliates, Sales Agents and Sub-Distributors comply with this clause 8.4. Should Diaxonhit or any of its
Affiliates contest the validity of the Trademark or the ownership thereof by XDx or its Affiliates, XDx may terminate this Agreement with immediate effect by giving written notice to Diaxonhit. Use of the Trademark by Diaxonhit and its Affiliates
will inure to the benefit of the owners thereof. 

  

	8.5	Diaxonhit shall only use the Trademark with the Product purchased from XDx or a Designee under this Agreement. 

  

	8.6	Diaxonhit and XDx shall, if necessary, promptly execute any necessary documents required by the laws of the Territory to record Diaxonhit as a licensee of the Trademark. Diaxonhit shall, when referring to the Trademark,
diligently comply with all relevant laws and regulations in force in the Territory and with all instructions provided by XDx. 

  
 17 

	8.7	XDx, with the assistance of Diaxonhit and its Affiliates, shall use commercially reasonable efforts to obtain, maintain and defend registrations of the Trademark in the Territory as of the Effective Date and as listed
in Schedule 3 in XDx’s own name and at its own cost, provided that if XDx declines to so maintain or defend, Diaxonhit shall have the right, as far as legally possible, to do so at their own cost and risk. 

 

	9.	SUPPLY OF PRODUCTS 

  

	9.1	XDx shall use commercially reasonable efforts to supply Diaxonhit, or have Diaxonhit supplied with, all of its and its Affiliates, Sales Agents and Sub-Distributors requirements of Product. Diaxonhit will provide XDx
with non-binding forecasts of its requirements for Products on a quarterly basis. 

  

	9.2	XDx may apply and vary minimum order quantities for the Products. In such case XDx will notify Diaxonhit. 

  

	9.3	Any delivery dates are estimates only and time of delivery is not of the essence but XDx shall use all reasonable endeavours to ensure that all orders for Products are fulfilled by XDx or the Designee in accordance with
the delivery dates specified in those orders. 

  

	9.4	All Product supplied pursuant to this Agreement shall, at the time of delivery thereof pursuant to clause 10, meet the Specification. 

 

	9.5	XDx shall have the right from time to time to appoint a Designee to manufacture and deliver the Product to Diaxonhit. Such manufacturing arrangements shall in no way alter the rights, obligations and liabilities of the
Parties under this Agreement. 

  

	9.6	Diaxonhit shall maintain customary quality control standards and record-keeping practices including, procedures for the handling of customer complaints and product recalls and maintaining quality control standards
relating to storage of the Product in accordance with the Specifications. 

  

	9.7	Diaxonhit shall keep XDx advised within agreed timescales of customer complaints relating to the Product and any information consistent with applicable legal and regulatory requirements. 

 

	10.	DELIVERY, TITLE AND RISK OF LOSS 

 XDx or the Designee shall deliver all Products to
Diaxonhit Free on Board (FOB), facility of XDx or its sub-contractor, as defined in INCOTERMS 2010. Title to all Products shall pass to Diaxonhit at the time and place of delivery. 

 

	11.	SAMPLE PRODUCTS 

 XDx shall supply Diaxonhit with the amount of Sample Product detailed
in Schedule 5 free of charge, and the additional amount of Sample Product detailed in Schedule 5 at the purchase price set forth therein, which Sample Product shall be packaged by Diaxonhit in a manner distinguishable from the Product for commercial
sale, and shall be Distributed by Diaxonhit in the Territory free of charge solely for training, Promotion and other internal purposes. Diaxonhit shall keep complete and accurate records in sufficient detail to evidence the amount of Sample Product
distributed by Diaxonhit in the Territory. 

  
 18 

 ***Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
  

	12.	XDX OBLIGATIONS 

  

	12.1	XDx shall co-operate with Diaxonhit and act in good faith to agree to the Testing Services Agreement(s) with the Testing Labs 

  

	12.2	Subject to Section 12.4, XDx will provide the following assistance to Diaxonhit and/or the [***] Lab and/or any other Testing Lab during the Term: 

 

	 	(A)	relevant training and training materials related to the Promotion, Distribution and operation of the Products and the Test; 

  

	 	(B)	free Test Plates as reasonably required by Dausset Lab or any other Testing Lab, but no more than [***] in each instance, to establish and validate procedures to operate the Test during the first [***] months following
the commencement of the Testing Services Agreement to be entered into with the Dausset Lab or other Testing Lab; 

  

	 	(C)	provide any assistance and Information reasonably required by Diaxonhit to assist with procedures and discussions with Regulatory Authorities to obtain reimbursement of the Test in any part of the Territory, if
required, and to obtain further required CE Mark and other Regulatory Approvals; 

  

	12.3	XDx shall provide Diaxonhit with copies of all promotional materials used in the United States relating to the Test and the Product that it produces at no cost to Diaxonhit. 

 

	12.4	Prior to the Launch Date, XDx will provide up to [***] man hours of training for Diaxonhit’s sales force, medical science liaisons and for Dausset Lab personnel. The training will be provided by XDx staff at its
premises in the USA or at a venue in France, as mutually agreed. In addition, XDx will provide free training from time to time at its premises in the USA or at a venue in France, as mutually agreed, where XDx has launched updated versions of the
Products or Test or has materially changed the Specifications. 

  

	12.5	Following the Launch Date, XDx shall provide reasonable support for such activities at an hourly rate of $[***], to be invoiced periodically to Diaxonhit and payable within 30 days of receipt of such invoices.

  

	13.	PURCHASE PRICE AND PAYMENT 

  

	13.1	Diaxonhit shall pay the then applicable Purchase Price (as listed in Schedule 2, Part A) for all Products delivered to Diaxonhit during each Sales Year for use for commercial sale in accordance with Section 13.4.

  

	13.2	No later than the 20th Working Day of each Quarter, Diaxonhit shall provide XDx with a quarterly report showing the Net Sales and Royalty due for the preceding Quarter (a “Royalty Report”). Such Royalty
Reports shall contain Net Sales and Test quantities in the Territory, on a country-by-country basis, as well as the number of AlloMap plates purchased, used and average Tests per AlloMap plate, together with any and all currency conversion
calculations used by Diaxonhit. XDx shall invoice Diaxonhit for the Royalty due. Provided that Diaxonhit receives XDx’s invoice by the end of the 15th Working Day of a calendar month then
Diaxonhit shall pay that invoice by the end of that calendar month: if the invoice is received after the end of the 15th Working Day of a calendar month then Diaxonhit shall pay that invoice by
the end of the following calendar month. 

  

	13.3	 Diaxonhit shall keep, and shall cause its Affiliates and Sales Agents to keep, true, accurate and complete records pertaining to the performance of
obligations under this Agreement, 

  
 19 

	 	
including gross sales of the Product (both in the aggregate and on a per Unit basis) and all other information necessary to determine the Net Sales Price, in sufficient detail to calculate all
fees and the Royalty payable pursuant to this Agreement and to prepare all reports required hereunder. 

  

	13.4	Promptly after delivery thereof, XDx shall invoice Diaxonhit for the Purchase Price of each shipment of Product ordered by and delivered to Diaxonhit. Diaxonhit shall pay in full each such invoice within thirty
(30) days of the end of the month in which it receives that invoice. If such payment is not made on the date due, then Diaxonhit shall pay interest to XDx calculated in accordance with the provisions of clause 27.9. 

 

	13.5	All payments made under this Agreement are calculated without regard to value added tax or any other Indirect Tax. If any such payment (together with any other Indirect Tax as applicable) constitutes for value added tax
purposes the whole or any part of the consideration for a taxable or deemed taxable supply made by any Party (the supplier) the amount of that payment shall be increased by an amount equal to the amount of value added tax which is chargeable in
respect of the taxable or deemed taxable supply in question, provided that the supplier shall have delivered a valid value added tax invoice in respect of such supply to the paying Party. If any payment is subject to any other Indirect Tax then the
amount of the payment shall be increased by an amount equal to such Indirect Tax and the paying Party shall in addition pay an amount equal to such Indirect Tax provided that a valid invoice has been issued in respect of that Indirect Tax. All
payments in respect of any Indirect Tax (including value added tax) shall be payable on the due date for payment of the original payment or, if later, the date on which a valid Indirect Tax invoice is received in respect of that Indirect Tax.
Diaxonhit shall issue invoices for all amounts payable under this Agreement consistent with Indirect Tax requirements and irrespective of whether the sums may be netted for settlement purposes. 

 

	13.6	Diaxonhit shall be responsible for any and all customs duties, clearance charges, brokers’ fees and other amounts payable in connection with the supply, importation and delivery of Products, as well as any and all
customs duties, clearance charges, brokers’ fees and other amounts payable in connection with the sale and export by XDx of Products. 

  

	13.7	The terms and conditions of sale set forth in this Agreement shall govern all purchases of Product by Diaxonhit from XDx or the Designee notwithstanding any additional or inconsistent terms or conditions on
Diaxonhit’s form of purchase order, XDx conditions of sale or similar document. 

  

	14.	NON CONFORMING PRODUCT 

  

	14.1	Diaxonhit shall be deemed to have waived all claims for damage, defects and shortage relating to the Product supplied by XDx or the Designee unless such claims are notified to XDx in writing within fifteen
(15) Working Days after delivery to Diaxonhit of the relevant shipment of Product; provided that in the event of a defect in the Product that could not reasonably have been detected by a customary inspection on delivery, Diaxonhit shall be
deemed to have waived all claims for damage, defects and shortage related thereto unless such claims are notified to XDx within fifteen (15) Working Days of discovering such defect but not later than six (6) months from the date of
delivery. 

  

	14.2	 In the event of a dispute between the Parties as to any claimed shortage, damage or defect in the Product (including whether any such shortage, damage
or defect occurred before or after delivery) that cannot be resolved within thirty (30) days of the claim being notified to XDx pursuant to clause 14.1, Diaxonhit and XDx shall within a further seven (7) days submit the batch of Product
concerned to an independent expert to be mutually agreed between the 

  
 20 

	 	
Parties (the “Independent Expert”) who shall examine the Product concerned. The decision of the Independent Expert shall be binding upon the Parties and the costs of the
Independent Expert shall be borne wholly by the Party against whom the Independent Expert decides. 

  

	14.3	Following a claim from Diaxonhit pursuant to clause 14.1, XDx shall, in the event that XDx accepts Diaxonhit’s claim as valid or in the event that the Independent Expert supports Diaxonhit’s claim, at
XDx’s sole option, replace free of charge any damaged or defective Product or to give Diaxonhit credit for such Product. Any Product which is agreed or determined to be damaged or defective shall (at XDx’s option) be either returned to XDx
or destroyed as specified by XDx, at XDx’s reasonable expense. 

  

	14.4	Subject to clause 22.1, in respect of claims for damage, defects or shortage referred to in clause 14.1, the remedies set out in clause 14.3 shall be Diaxonhit’s sole remedy; provided that this clause 14.4 shall
not limit XDx’s obligations pursuant to clause 19.2(C) and 19.2 (D). Notwithstanding anything herein to the contrary, XDx shall have no liability for damage or defects to Product occurring after delivery thereof pursuant to clause 10.

  

	15.	PRODUCT RECALL 

  

	15.1	Product may be recalled by XDx for any of the following reasons: 

  

	 	(A)	where required by Applicable Laws and Regulations; 

  

	 	(B)	following an order to recall by any Regulatory Authority; or 

  

	 	(C)	where XDx determines that recall is necessary or advisable for safety reasons. 

 Diaxonhit shall
administer all aspects of any Product recall in accordance with provisions of this clause 15. 
  

	15.2	If Diaxonhit determines that any Product should be recalled, or if Diaxonhit becomes aware that a recall is required by law, then Diaxonhit shall notify XDx in writing within twenty-four (24) hours of such
determination and shall consult with XDx regarding the most appropriate course of action. XDx shall review the written notice and provide a written response to Diaxonhit within twenty-four (24) hours of receipt of Diaxonhit’s notice of
such determination. Diaxonhit shall give XDx notice of any life endangering situation or requirement for a recall of any Product mandated by any Regulatory Authority promptly. 

 

	15.3	If XDx determines that any Product should be recalled because of safety reasons, XDx shall notify Diaxonhit in writing within twenty four (24) hours of such determination and the reason for such recall and
Diaxonhit shall proceed with the recall in accordance with Diaxonhit’s recall procedures and any reasonable instructions provided by XDx. 

  

	15.4	Following the decision to recall any Product, XDx shall provide Diaxonhit with a prepared statement for use in response to any inquiries regarding any recall of the Product. Diaxonhit shall use such prepared statement
to respond to any inquiries received with regard to the recall and shall not make any other statement regarding such recall. 

  

	15.5	Subject to a cap of 100% of the Royalties actually received by XDx in the Sales Year in which a recall occurs, if any Product is recalled, XDx shall reimburse Diaxonhit for the direct out-of-pocket costs of activities
incurred as a result of the recall, (e.g., travel, transportation, destruction and publicity costs) except those internal costs directly incurred and necessary to administer the recall; provided, however, that XDx shall not reimburse any costs
associated with the recall to the extent that such recall is due to the fault, negligence, recklessness or wrong-doing of Diaxonhit or any of Diaxonhit’s Affiliates or Sales Agents, or their directors, officers, employees or agents or due to a
breach of this Agreement by Diaxonhit. 

  
 21 

	15.6	In addition to its obligations under clause 2.7, Diaxonhit shall keep complete and accurate records of the Distribution of the Product, including methods for tracking and traceability as required under Applicable Laws
and Regulations, to enable appropriate procedures to be implemented in the event that a voluntary or mandatory recall of any Product is required. 

  

	15.7	XDx shall be entitled to inspect and audit at any reasonable time Diaxonhit’s recall procedures and the records referred to in clause 15.6, to satisfy itself that Diaxonhit is complying with its obligations under
clause 15. However, this clause 15.7 shall not relieve Diaxonhit of its responsibilities and liabilities arising from clause 15. 

  

	15.8	In the event that any Product is recalled pursuant to this clause 15, the obligations of Diaxonhit to sell and Promote the Product affected by the recall and of XDx to supply the Product to Diaxonhit pursuant to this
Agreement shall be suspended in whole, or, at the decision of XDx in part cases where recall only affects part of the Territory. The suspension shall only be lifted if and when the circumstances that caused the recall of the Product have been
resolved. If the Product is thereafter totally withdrawn from the market in the Territory then XDx may terminate this Agreement under clause 24.2(D). 

  

	16.	TRADEMARK AND PATENT INFRINGEMENT 

  

	16.1	Each Party shall give prompt notice to the other if either Party becomes aware of any of the following within the Territory: 

  

	 	(A)	an infringement or threatened infringement of the Patents; 

  

	 	(B)	any infringement or threatened infringement of the Trademark or XDx’s rights protecting any label, trade name, trade dress, service mark or device used in connection with the Product; 

 

	 	(C)	or any claim by a third party that the sale of the Products infringes the third party’s patents, trademarks or other intellectual property rights; 

each “an IP Action”. 
  

	16.2	XDx Action 

 XDx shall have the right, but not the obligation, to take action in the
prosecution, defence, prevention, or termination of any IP Action. Should XDx elect to commence or defend legal proceedings in respect of the IP Action and Diaxonhit is joined as party in any such proceedings, Diaxonhit shall have the right to
approve the counsel selected by XDx to represent the parties, such approval not to be unreasonably withheld. The expenses of such legal proceedings, including any reasonable expenses of Diaxonhit incurred in conjunction with such legal proceedings
or the settlement thereof, shall be paid for entirely by XDx and XDx shall hold Diaxonhit free, clear and harmless from and against any and all costs of such litigation, including reasonable attorney’s fees (but excluding any independent
attorney fees incurred by Diaxonhit in addition to the approved attorney fees). XDx shall not compromise or settle such litigation in a matter that would admit fault on behalf of Diaxonhit or adversely affect Diaxonhit’s rights without the
prior written consent of Diaxonhit, which consent shall not be unreasonably withheld or delayed. In the event XDx exercises its right to conduct legal proceedings pursuant to this clause 16.2, it shall first reimburse itself out of any sums
recovered in such suit or in settlement thereof for all out of pocket costs and expenses of 

  
 22 

 
every kind and character, including without limitation attorney’s fees and the costs of Diaxonhit payable pursuant to this clause 16.2, incurred in the conduct of any such legal proceedings.
If, after such reimbursement, any funds shall remain from said recovery, then Diaxonhit shall be entitled to receive 75% of such funds and the remaining 25% of such funds shall be retained by XDx. 

 

	16.3	Diaxonhit Action 

 If XDx does not take action in the prosecution, defence, prevention,
or termination of any IP Action pursuant to clause 16.2 above, and has not commenced negotiations with the other party for the discontinuance of said IP Action, within ninety (90) days after receipt of notice to XDx by Diaxonhit of the
existence of an IP Action, Diaxonhit may elect to do so. Should Diaxonhit elect to commence or defend legal proceedings in respect of the IP Action and XDx is joined as party in any such legal proceedings, XDx shall have the right to approve the
counsel selected by Diaxonhit to represent the Parties, such approval not to be unreasonably withheld or delayed. The expenses of such suit or suits that Diaxonhit elects to bring, including any expenses of XDx incurred in conjunction with the
prosecution of such suits or the settlement thereof, shall be paid for entirely by Diaxonhit, as the case may be, and Diaxonhit shall hold XDx free, clear and harmless from and against any and all costs of such litigation, including reasonable
attorney’s fees (but excluding any independent attorney fees incurred by XDx in addition to the approved attorney fees). Diaxonhit shall not compromise or settle such litigation without the prior written consent of XDx, which consent shall not
be unreasonably withheld or delayed. In the event Diaxonhit exercises its right to pursue legal proceedings pursuant to this clause 16.3, Diaxonhit shall first reimburse themselves out of any sums recovered in such suit or in settlement thereof for
all out of pocket costs and expenses of every kind and character, including without limitation attorney’s fees and the costs of XDx payable pursuant to this clause 16.3, incurred in the prosecution of any such suit. If, after such
reimbursement, any funds shall remain from said recovery, then XDx shall be entitled to receive 25% of such funds and the remaining 75% of such funds shall be retained by Diaxonhit. 

 

	16.4	Each Party shall always have the right to be represented by counsel of its own selection and at its own expense in any legal proceedings conducted under this clause 16 by the other party in respect of an IP Action.

  

	16.5	Each party agrees to cooperate fully in any action under this clause 16 which is controlled by the other party, provided that the controlling party reimburses the cooperating party promptly for any costs and expenses
incurred by the cooperating party in connection with providing such assistance. 

  

	16.6	If a party lacks standing and the other party has standing to bring any such suit, action or proceeding, then such other party shall do so at the request of and at the expense of the requesting party. If either party
determines that it is necessary or desirable for another party to join any such suit, action or proceeding, the other party shall execute all papers and perform such other acts as may be reasonably required in the circumstances. 

 

	17.	REPRESENTATIONS AND WARRANTIES 

  

	17.1	Each Party hereby represents and warrants to the other that: 

  

	 	(A)	it is duly authorised to enter into this Agreement; 

  

	 	(B)	it has and will maintain and comply with all consents, approvals and licences necessary for it to enter into and perform this Agreement; and 

 

	 	(C)	its entry into and performance of this Agreement does not and will not conflict with any of its other contractual obligations or with any Applicable Laws and Regulations. 

  
 23 

	18.	COMPLIANCE/ANTI-CORRUPTION LAWS/EXPORT CONTROL 

  

	18.1	Each Party shall at all times during the Term be an entity that is appropriately authorized to perform its obligations under this Agreement under Applicable Laws and Regulations and shall at all times have a sufficient
financial resources to meet its obligations under this Agreement. 

  

	18.2	Each Party shall inform the other in the event that it receives a formal notification that it is the target of a formal investigation by a Regulatory Authority for a Material Anti-Corruption Law Violation.

  

	18.3	Diaxonhit shall not enter into any transaction in any country or with any Person if such transaction is restricted under United States, United Nations, European Union or other Applicable Laws and Regulations regarding
exports (“Export Regulations”) (irrespective of whether Diaxonhit itself is subject to such Export Regulations) without having first obtained all Regulatory Approvals and the prior written approval of XDx. 

 

	19.	INDEMNIFICATION 

  

	19.1	In addition to any other remedy available to XDx, but subject to the provisions of clauses 9.3 and 14.4, Diaxonhit shall defend, indemnify and hold harmless XDx, its Affiliates and its and their respective officers,
directors, shareholders, employees and agents from and against any and all Loss incurred by them to the extent resulting from, arising out of, or in connection with any Third Party Claim against XDx, its Affiliates or its or their respective
officers, directors, partners, shareholders, employees or agents that arises or results from: 

  

	 	(A)	Any breach of any obligation in this Agreement by or on behalf of Diaxonhit or its Affiliates, Sub-Contractors or Sales Agents, or the wilful misconduct, negligence or bad faith by or on behalf of Diaxonhit or its
Affiliates, Sub-Contractors or Sales Agents; 

  

	 	(B)	the inaccuracy or breach of any representation or warranty made by Diaxonhit in this Agreement; or 

  

	 	(C)	any personal injury or death to any third party resulting from the use of or failure of any Products that did not comply with clause 9.4, which noncompliance could reasonably have been detected by a customary inspection
on delivery; 

 except to the extent such Losses arise as a result of the negligence, fraud, wilful misconduct or wrongful act
of XDx, its Affiliates, or its or their respective officers, directors, partners, shareholders, employees or agents. 
  

	19.2	In addition to any other remedy available to Diaxonhit, but subject to the provisions of clauses 9.3 and 14.4, XDx shall defend, indemnify and hold harmless Diaxonhit, its Affiliates and Sales Agents and its and their
respective officers, directors, shareholders, employees and agents from and against any and all Loss incurred by them to the extent resulting from, arising out of, or in connection with any Third Party Claim against Diaxonhit, its Affiliates or
Sales Agents, or its or their respective officers, directors, partners, shareholders, employees or agents that arises or results from: 

  

	 	(A)	Any breach of any obligation in this Agreement by or on behalf of XDx or its Affiliates, or the wilful misconduct, negligence or bad faith by or on behalf of Diaxonhit or its Affiliates; 

  
 24 

	 	(B)	the inaccuracy or breach of any representation or warranty made by XDx in this Agreement; 

  

	 	(C)	any claim that a Products, the Test or any process required to operate the Test infringes the Intellectual Property Rights of a Third Party; or 

 

	 	(D)	any personal injury or death to any third party resulting from the use of or failure of any Products that did not comply with clause 9.4, which noncompliance could not reasonably have been detected by a customary
inspection on delivery, 

 except to the extent such Losses arise as a result of the negligence, fraud, wilful misconduct or
wrongful act of Diaxonhit, its Affiliates or Sales Agents, or its or their respective officers, directors, partners, shareholders, employees or agents. 
  

	20.	INDEMNITY ACTIONS 

  

	20.1	An Indemnified Party shall promptly and without delay give the Indemnifying Party prompt written notice of any Loss or discovery of fact upon which such Indemnified Party intends to base a request for indemnification
under this Agreement (an “Indemnification Claim Notice”). In no event shall the Indemnifying Party be liable for any Loss that results from any delay in providing the Indemnification Claim Notice. Each Indemnification Claim Notice
shall contain a description of the claim and the nature and amount of the Loss claimed (to the extent that the nature and amount of such Loss is known at such time). The Indemnified Party shall furnish promptly to the Indemnifying Party copies of
all papers and official documents received in respect of any such Loss. For the avoidance of doubt, all indemnification claims in respect of a Party, its Affiliates or their respective directors, officers, employees and agents (each, an
“Indemnitee”) shall be made solely by such Party to this Agreement. 

  

	20.2	The obligations of an Indemnifying Party under this Agreement with respect to a Third Party Claim shall be governed by and be contingent upon the following: 

 

	 	(A)	Assumption of Defence 

 At its option, the Indemnifying Party may assume the defence of
any Third Party Claim by giving written notice to the Indemnified Party within fourteen (14) days after the Indemnifying Party’s receipt of an Indemnification Claim Notice. The assumption of the defence of a Third Party Claim by the
Indemnifying Party shall not be construed as an acknowledgement that the Indemnifying Party is liable to indemnify any Indemnitee in respect of the Third Party Claim, nor shall it constitute a waiver by the Indemnifying Party of any defences it may
assert against any Indemnified Party’s claim for indemnification. 
  

	 	(B)	Control of the Defence 

 Upon the assumption of the defence of a Third Party Claim by
the Indemnifying Party: 
  

	 	(1)	the Indemnifying Party may appoint as lead counsel in the defence of the Third Party Claim any legal counsel selected by the Indemnifying Party which shall be reasonably acceptable to the Indemnified Party; and

  
 25 

	 	(2)	the Indemnifying Party shall not be liable to the Indemnified Party for any legal expenses subsequently incurred by such Indemnified Party in connection with the analysis, defence or settlement of the Third Party Claim.
In the event that it is ultimately determined that the Indemnifying Party is not obligated to indemnify, defend or hold harmless an Indemnitee from and against the Third Party Claim, the Indemnified Party shall reimburse the Indemnifying Party for
any and all costs and expenses (including lawyers’ fees and costs of suit and a solicitor client basis) incurred by the Indemnifying Party in its defence of the Third Party Claim with respect to such Indemnified Party or Indemnitee.

  

	 	(C)	Right to Participate in the Defence  

 Without limiting clauses 20.2(A) and 20.2(B) any
Indemnitee shall be entitled to participate in, but not control, the defence of a Third Party Claim and to retain counsel of its choice for such purpose; provided, however, that such retention shall be at the Indemnitee’s own expense unless the
Indemnifying Party has failed to assume the defence and retain counsel in accordance with clause 20.2(A) (in which case the Indemnified Party shall control the defence). 
  

	 	(D)	Settlement 

 With respect to all Losses in connection with Third Party Claims, where the
Indemnifying Party has assumed the defence of a Third Party Claim in accordance with clause 20.2(A), (i) the Indemnifying Party shall have authority to consent to the entry of any judgement, enter into any settlement or otherwise dispose of
such Loss, provided that it obtains the prior written consent of the Indemnified Party which consent shall not be unreasonably withheld or delayed and (ii) no Indemnified Party or Indemnitee shall admit any liability with respect to, or settle,
compromise or discharge, any such Third Party Claim without the prior written consent of the Indemnifying Party, which consent shall not be unreasonably withheld. 
  

	 	(E)	Cooperation 

 If the Indemnifying Party chooses to defend or prosecute any Third Party
Claim, at the Indemnifying Party’s request, the Indemnified Party shall, and shall cause each other Indemnitee to, reasonably cooperate in the defence or prosecution thereof and shall furnish such records, information and testimony, provide
such witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith. Such cooperation shall include access during normal business hours by the Indemnifying Party to,
and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Third Party Claim, and making the Indemnified Party and its employees and agents available on a mutually convenient basis to provide
additional information and explanation of any records or information provided, and the Indemnifying Party shall reimburse the Indemnified Party for all its related reasonable out-of-pocket expenses. 

 

	21.	NO IMPLIED WARRANTIES 

  

	21.1	All conditions, warranties and other terms not expressly set out in this Agreement (whether implied by statute, custom, course of dealing or otherwise) are excluded to the maximum extent permitted by law, including:

  

	 	(A)	any term as to satisfactory quality, merchantability or fitness for a particular purpose; 

  
 26 

	 	(B)	any term arising from course of performance, course of dealing or usage in the trade; or 

  

	 	(C)	any term as to description or otherwise created by any affirmation of fact or promise or sample or model. 

  

	21.2	Except as expressly set out in this Agreement, no Party (or any of its Affiliates) shall have any liability of any nature with regard to the value, adequacy, freedom from fault or infringement, quality, efficacy,
safety, suitability, characteristics, validity or usefulness of the Trademark, the Patents, the Information or other information provided under this Agreement or the Products. 

 

	21.3	Without prejudice to the generality of clause 21.1, XDx makes no representation or warranty to Diaxonhit that: 

  

	 	(A)	any Regulatory Approval will be obtained and/or maintained; 

  

	 	(B)	that the patent applications included within the Patents will be granted; 

  

	 	(C)	the Patents and Trademark are valid and in force and will remain valid and in force; or 

  

	 	(D)	the Products will not infringe any third party patents, trademarks or other intellectual property rights. 

  

	21.4	Nothing in this clause 21 or any other provision of this Agreement shall exclude or limit liability for fraud or fraudulent misrepresentation. 

 

	22.	LIMITATION OF LIABILITY 

  

	22.1	Nothing in this Agreement limits or excludes a Party’s liability: 

  

	 	(A)	for death or personal injury arising out of negligence; 

  

	 	(B)	fraud, fraudulent misrepresentation, criminal acts or the tort of deceit; or 

  

	 	(C)	where such a limitation or exclusion would be contrary to applicable law. 

  

	22.2	Subject to clause 22.1 neither Party nor any of its Affiliates shall be liable to the other Party or its Affiliates in contract (including for damages for any deliberate repudiatory acts), tort (including negligence),
for breach of statutory duty, or otherwise: 

  

	 	(A)	for any indirect, special, exemplary, or consequential loss of any kind whatsoever however caused; 

  

	 	(B)	for any loss that consists of loss of goodwill, reputation business, revenue, profit, saving or use of money (in each case whether direct or indirect); or 

 

	 	(C)	for any loss that consists of the loss or corruption of data, 

 even if the relevant Party has
been advised of the possibility of that type of loss. 

  
 27 

	22.3	Subject to clause 22.1, the aggregate liability of Diaxonhit, its Affiliates and Agents to XDx (or any Affiliate of XDx), whether in contract (including for damages for any deliberate repudiatory acts), tort
(including negligence), for breach of statutory duty or otherwise, arising under or in connection with this Agreement shall not exceed the following amounts: 

  

	 	(A)	for loss representing damage to physical property, US$750,000; and 

  

	 	(B)	for all other losses, the greater of US$1,000,000 and 110% of the amounts paid or payable under this Agreement. 

  

	22.4	Subject to clause 22.1, the aggregate liability of XDx and its Affiliates to Diaxonhit (or any Affiliate of Diaxonhit), whether in contract (including for damages for any deliberate repudiatory acts), tort
(including negligence), for breach of statutory duty or otherwise, arising under or in connection with this Agreement shall not exceed the following amounts: 

  

	 	(A)	for loss representing damage to physical property, US$750,000; and 

  

	 	(B)	for all other losses, the greater of US$1,000,000 and 110% of the amounts paid or payable under this Agreement. 

  

	22.5	Each Party shall, at the request of the other Party (and shall procure that its Affiliates shall) execute all deeds and other documents in favour of members of the other Party and its Group to enable each of them to
enforce the limitations and exclusions in this clause 22. 

  

	23.	CONFIDENTIALITY 

  

	23.1	Subject to clause 23.5 neither Party nor its Affiliates or Sales Agents shall disclose any trade secret, proprietary or confidential information (including the Information) received from the other Party or an Affiliate
or Sales Agent of the other Party pursuant to this Agreement or any previous agreements between the Parties or their Affiliates or Sales Agents relating to the Products or the Substance (“Confidential Information”) without the other
Party’s written consent. The following information shall not be considered Confidential Information: 

  

	 	(A)	information that was known to the receiving Party at the time of its disclosure as evidenced by written records provided such information was not subject to any obligation of confidentiality; 

 

	 	(B)	information disclosed to the receiving Party by a third party without any duty of confidentiality; 

  

	 	(C)	information that is in the public domain other than by a breach by the receiving Party of any obligation of confidence; or 

  

	 	(D)	information independently generated by the receiving Party without reference to the Confidential Information of the other Party. 

  

	23.2	Except as contemplated by clause 23.5, Diaxonhit undertakes not to disclose the existence and/or the terms of this Agreement or its relationship with XDx to any third party nor in connection with any advertising without
XDx’s written consent. 

  

	23.3	Either Party may disclose Confidential Information to an Affiliate or Sales Agent, provided such Affiliate or Sales Agent, as the case may be, agrees to be bound by the provisions of this clause 23. 

  
 28 

 ***Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
  

	23.4	Each Party agrees that it and its Affiliates and Sales Agents shall not use Confidential Information for any purpose other than permitted by this Agreement without the prior written approval of the other Party.

  

	23.5	This Agreement shall not restrict the receiving Party from complying with any legal requirement to disclose Confidential Information provided that the receiving Party shall to the extent that it is not prohibited from
doing so by Applicable Laws and Regulations, promptly notify the disclosing Party of such legal requirement so that the disclosing Party may seek to quash such order and to obtain a protective order requiring that the relevant Confidential
Information be held in confidence by such court or agency or, if disclosed, be used only for the purposes for which the order was issued. The receiving Party shall cooperate fully with the disclosing Party in any such proceedings. 

 

	23.6	The confidentiality obligations set out in this clause 23 shall survive the termination or expiry of this Agreement for five (5) years. 

 

	23.7	Diaxonhit shall ensure that each of its employees and Sub-contractors (including Sales Agents and Sub-Distributors) who have access to the Confidential Information have agreed to be bound by obligations of
confidentiality and non-use at least as protective as those which apply to Diaxonhit under this Agreement. 

  

	23.8	Notwithstanding anything set forth in this clause 23 or otherwise, XDx shall not be obligated to keep any information related to the Products confidential or be restricted in its use of such information to the extent
such Information is necessary for the Promotion of the Products. 

  

	24.	TERM AND TERMINATION 

  

	24.1	This Agreement shall commence on the Effective Date and shall be in effect until the later of: 

  

	 	(A)	The expiration of the last to expire Patent in the Territory; and 

  

	 	(B)	10 years from the Launch Date; 

 (the “Initial Term”) unless earlier terminated
as set forth in clause 24.2 and provided always that Diaxonhit shall have the option to extend the Agreement for successive 12 month periods at the end of this Initial Term by serving notice at least 3 months prior to the end of the then current
term, and subject always to the Royalty being reduced to [***]% of Net Sales for that period or such other rate as the Collaboration Committee shall agree based on prevailing market conditions,. 

 

	24.2	This Agreement may be terminated upon: 

  

	 	(A)	either Party giving not less than ninety (90) days written notice to the other Party of a breach of any of the terms of this Agreement by such other Party and the other Party’s failure to cure such breach
within the notice period; 

  

	 	(B)	either Party giving written notice to the other Party, which termination notice shall have immediate effect, in the case of the other Party being subject to an Insolvency Event, such notice having immediate effect;

  

	 	(C)	 either Party giving not less than twelve (12) months’ written notice to other Party in the event of a Change in Control of that other Party,
such notice to be served within one hundred and eighty (180) days of receiving notice of that Change of Control or within two hundred and seventy (270) days of receiving notice where the Person (or an Affiliate of the Person) acquiring
Control of the other Party owns a Competing 

  
 29 

	 	
***Confidential material redacted and filed separately with the Securities and Exchange Commission. 

  

	 	Product. As soon as it is lawfully able to do so after the occurrence of a Change of Control, a Party which is the subject of a Change of Control shall notify the other Party of that Change of Control.

  

	 	(D)	Diaxonhit giving XDx written notice in the event that the Products is totally withdrawn or loses its CE Mark in respect of any Product and such CE Mark loss is not remedied within 3 months of the event of loss. In such
instance, termination of the Agreement will occur immediately upon Diaxonhit giving such notice; 

  

	 	(E)	either Party giving written notice to the other Party in the event of any publicly announced investigation by a Regulatory Authority relating to any suspected or actual Material Anti-Corruption Law Violation by the
other Party or any Affiliates, consultants, agents, representatives or sub-contractors (including any Sub-Contractors) of that other Party or its Affiliates connected with this Agreement; 

 

	 	(F)	either Party giving twelve (12) months’ written notice to the other Party in the event that the average reimbursement for the Test in [***] or [***] falls below [***] Euros €[***] per Test over the course
of a Quarter, provided that such notice cannot be served before the first anniversary of the Effective Date; 

  

	 	(G)	either Party giving notice to the other Party in the circumstance and in the manner set out in clauses 7.3 or 27.5. 

  

	25.	CONSEQUENCES OF TERMINATION 

  

	25.1	In the event of expiry or termination of this Agreement, howsoever such termination occurs: 

  

	 	(A)	Each of Diaxonhit and XDx shall stop and shall cause their Affiliates and Sales Agents to stop using all Confidential Information of the other Party and upon the other Party’s request shall return to the requesting
Party all Confidential Information; provided that Diaxonhit shall be entitled to continue using such Confidential Information supplied by XDx only for the purposes of selling its current stocks of the Products in accordance with the provisions of
clause 25.3, or fulfilling any applicable regulatory requirement. 

  

	 	(B)	Diaxonhit and its Affiliates and Sales Agents shall stop using the Trademark and any other trademarks, trade names, trade dress, service marks or devices applied to or used in association with the Products which are the
property of XDx, except for the purposes of selling its remaining stocks of the Products in accordance with the provisions of clause 25.3. The licenses granted to Diaxonhit shall terminate. 

 

	 	(C)	Diaxonhit shall within thirty (30) days (or ninety (90) days if necessary to effectuate the provisions of clause 25.3) transfer the ownership of any Regulatory Approvals relating to the Products to XDx or
XDx’s designee or, upon XDx’s request cancel the Regulatory Approvals, and take all measures to perfect XDx’s or its designee’s rights thereto, all of the forgoing at Diaxonhit’s cost. No compensation shall be due to
Diaxonhit or its Affiliates for such assignment. 

  

	25.2	Termination of this Agreement shall not relieve the Parties of any accrued liability. 

  

	25.3	Where this Agreement expires at the end of the Term or is terminated by XDx pursuant to clause 24.2(A), Diaxonhit shall have a period of ninety (90) days from the effective date of termination of this Agreement
during which it may sell in the Territory its stocks of the Products remaining at the effective date of such termination. 

  
 30 

 ***Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
  

	25.4	Where this Agreement is terminated by Diaxonhit or by XDx (other than pursuant to clause 24.2(A) or (E), XDx shall or shall procure that an Affiliate of XDx shall; 

 

	 	(A)	repurchase all unused Products from Diaxonhit at the original Purchase Price, subject to Diaxonhit’s reasonable efforts to utilize such unused Products in the ordinary course of business following notice of
termination; 

  

	 	(B)	reimburse Diaxonhit for any unamortised and documented costs incurred in the Promotion and Distribution of the Products and the Test, including investments in equipment for the Dausset Lab (including centrifuges for
sample collections in all Territory hospitals), up to a maximum of [***] Euros (€[***]); and 

  

	 	(C)	pay a royalty to Diaxonhit of [***]% of the Net Sales achieved by XDx in those countries within the Territory where Diaxonhit Promoted the Test during the Term, such royalty to be calculated and paid to Diaxonhit in the
same manner as the Royalty was calculated and paid to XDx during the Term. 

  

	25.5	Within a period of ninety (90) days from the termination of this Agreement, Diaxonhit and its Affiliates shall, at Diaxonhit’s discretion either destroy all or transfer to XDx all Promotional Materials
relating to the Products then in Diaxonhit’s or its Affiliates’ possession. 

  

	25.6	Clauses 1, 8, 14, 15, 19, 20, 21, 22, 23, 25 and 27 and all provisions which by their nature are intended to survive shall survive expiry or termination of this Agreement. 

 

	26.	ASSIGNMENT 

 This Agreement may not be assigned by either Party in whole or in part
without the prior written consent of the other, except that either Party may assign this Agreement and its rights and obligations hereunder to any of its Affiliates or any successor in interest to all or substantially all of the assets or business
to which this Agreement relates without such consent. 
  

	27.	GENERAL PROVISIONS 

  

	27.1	Amendment 

 Any amendment or modification of this Agreement must be in writing and signed
by authorised representatives of all Parties. 
  

	27.2	Entire Agreement 

 This Agreement and any documents or ancillary agreements, including
the Test Service Agreement to be entered in to with the Dausset Lab referred to in it constitute the entire agreement between the Parties with respect to its subject matter. This Agreement supersedes all prior arrangements, undertakings,
understandings or agreements, whether written or oral, with respect to its subject matter. Each Party confirms that in entering into this Agreement it is not relying on any statements, representations, warranties or covenants of any person (whether
a Party or not) except as specifically set out in this Agreement including any such statements, representations, warranties or covenants made by a Party or its representatives prior to entering into this Agreement. Each Party waives all rights and
remedies which, but for this clause, might otherwise be available to it in respect of any such representation, warranty, collateral contract or other assurance. All Schedules and Exhibits referred to in this

  
 31 

 
Agreement are intended to be and are hereby specifically incorporated into and made a part of this Agreement. This clause 27.2 shall not exclude or limit liability for fraud or fraudulent
misrepresentation. 
  

	27.3	Audit Rights 

 XDx shall have the right, at its own expense, to access the books and records of
Diaxonhit, its Affiliates and Sales Agents, as may be reasonably necessary to verify the accuracy of the gross and Net Sales in Sections 13.2 and 13.3. Such access shall be conducted no sooner than 15 Working Days’ prior written notice to and
during ordinary business hours, will be conducted in a manner that is not disruptive to Diaxonhit’s operations, and shall not be more frequent than once per Sales Year. As it relates to the calculation of sales, if such independent certified
public accountant’s report shows any underpayment by Diaxonhit, Diaxonhit shall remit to XDx within thirty (30) days after Diaxonhit’s receipt of such report, (a) the amount of such underpayment, and (b) if such underpayment
exceeds five percent (5%) of the total amount owed for the period then being audited, the reasonable fees and expenses of any independent accountant performing the audit on behalf of XDx. Any audit or inspection conducted under this Agreement
by XDx or its agents or contractors will be subject to the confidentiality provisions of this Agreement, and XDx will be responsible for compliance with such confidentiality provisions by such agents or contractors. 

If any dispute arises under this Section 27.3 between the Parties relating to underpayments and the Parties cannot resolve such dispute within thirty
(30) days of a written request by either Party to the other Party, the Parties shall hold a meeting, attended by the Chief Executive Officer or President of each party (or their respective designees), to attempt in good faith to negotiate a
resolution of the dispute. If, within sixty (60) days after such meeting request, the Parties have not succeeded in negotiating a resolution of the dispute, either Party may pursue any other available remedy, including, upon prior written
notice to the other Party, instituting legal action. 
  

	27.4	Expenses 

 Except as otherwise expressly provided in this Agreement, each Party shall pay
the fees and expenses of its respective lawyers and other experts and all other expenses and costs incurred by such Party incidental to the negotiation, preparation, execution and delivery of this Agreement. 

 

	27.5	Force Majeure  

 No liability shall result from delay in performance or non-performance,
in whole or in part, by either of the Parties to the extent that such delay or non-performance is caused by an event of Force Majeure. “Force Majeure” means an event that is beyond a non-performing Party’s reasonable control,
including acts of God, strikes, lock-outs or other industrial/labour disputes, war, riot, civil commotion, terrorist act, malicious damage, epidemics, quarantines, fire, flood, storm or natural disaster. The Force Majeure Party shall, within five
(5) days of the occurrence of the Force Majeure event, give written notice to the other Party stating the nature of the Force Majeure event, its anticipated duration and any action being taken to avoid or minimize its effect. Any suspension of
performance shall be of no greater scope and of no longer duration than is reasonably required and the Force Majeure Party shall use best endeavours without being obligated to incur any material expenditure to remedy its inability to perform;
provided, however, if the suspension of performance continues for sixty (60) days after the date of the occurrence and such failure to perform would constitute a material breach of this Agreement in the absence of such event of Force Majeure,
the Parties shall meet and discuss in good faith any amendments to this Agreement to permit the other Party to exercise its rights under this Agreement. If the Parties are not able to agree on such amendments within thirty (30) days and if
suspension of performance continues, such other Party may 

  
 32 

 
terminate this Agreement immediately by written notice to the Force Majeure Party, in which case neither Party shall have any liability to the other except for those rights and liabilities that
accrued prior to the date of termination. 
  

	27.6	Further Assurance 

 Each Party shall perform all further acts and execute and deliver
such further documents as may be necessary or as the other Party may reasonably require to implement or give effect to this Agreement. 
  

	27.7	Governing Law and Dispute Resolution 

  

	 	(A)	The interpretation and construction of this Agreement shall be governed by the laws of England. Except as otherwise provided in clause 14.2 or this clause 27.7, any dispute, controversy or claim arising out of or in
connection with this Agreement or the breach, termination or invalidity thereof (“Dispute”), shall be finally settled by arbitration in accordance with the JAMS International Arbitration Rules. The arbitral tribunal shall be
composed of three (3) arbitrators. The seat of arbitration shall be London. The language to be used in the arbitral proceedings shall be English. The proceedings, including any outcome, shall be confidential. 

 

	 	(B)	The Parties shall endeavour to resolve any Dispute by escalation to their management provided that this shall not prevent a Party taking any action under this clause 27.7. 

 

	 	(C)	Nothing in this clause 27.7 shall prejudice howsoever any Party’s right to apply, either prior to or during any arbitration, to any court of competent jurisdiction for interim, provisional or conservatory measures,
relief or remedies, including a temporary restraining order, preliminary injunction or other interim relief, concerning a dispute if necessary to protect the interests of such Party or to preserve the status quo pending the arbitration proceeding.

  

	 	(D)	A breach by either Party of clause 18 or 23 will cause irreparable damage and the non-breaching Party will not be adequately compensated by monetary damages. In the event of any proceedings brought pursuant to clause
27.7(C) arising out of a breach, or threatened breach, of clause or 23, the non-breaching Party shall not be required to prove irreparable injury or actual damages as a remedy or to post a bond or provide security for costs. 

 

	27.8	Insurance 

 Each Party shall maintain during the Term and for three (3) years
thereafter insurance coverage of the types and in the amounts typically carried by companies in the medical testing industry in relation to the sale and distribution of Products such as the Products in the jurisdictions covered by the Territory or
in such types and amounts as stipulated by XDx in writing prior to the Effective Date. Each Party shall provide the other Party with certificates evidencing its insurance coverage and limits on request. 

 

	27.9	Interest 

 If either Party does not make payment to the other Party under this Agreement
by the required date (“Due Date”), it shall pay interest to the other Party at the rate of two per cent (2%) per annum above London Interbank Offered Rate as published by Reuters (LIBOR) for the currency of payment (or, if
lower the maximum rate permitted by law) on a daily basis from the Due Date up to and including the actual date of payment. This clause 27.9 shall not affect or limit any other remedy. 

  
 33 

	27.10	No Benefit to Others 

  

	 	(A)	This Agreement may be enforced by any Affiliate of XDx. 

  

	 	(B)	Except as provided in clause 27.10(A), a Person who is not a Party shall not have any right under Applicable Laws or Regulations or otherwise to enforce any term of this Agreement. 

 

	 	(C)	The right of the Parties to terminate, rescind or agree any variation of or waiver or settlement under this Agreement is not subject to the consent of any Person that is not a Party. 

 

	27.11	Notices 

  

	 	(A)	Any notice, request, or other communication required under this Agreement shall be in writing, shall refer specifically to this Agreement, and shall be hand delivered, sent by a recognized overnight delivery service,
costs prepaid, or sent by facsimile (with transmission confirmed), addressed to the Parties at their respective addresses above or such other addresses notified in accordance with this clause 27.11. 

 

	 	(B)	Each Party shall from time to time notify each other of the facsimile numbers to use for such purposes, and in the absence of a separate notification the facsimile number to be used are: 

 

	 	(1)	XDx: +1 415 287 2461; and 

  

	 	(2)	Diaxonhit + 33 1 58 05 47 19 

  

	 	(C)	Notices shall be deemed to have been given as on the date delivered by hand or transmitted by facsimile (with transmission confirmed), or on the second day after deposit with an internationally recognized overnight
delivery service. 

  

	 	(D)	Any notice delivered by facsimile shall be confirmed by a hard copy delivered as soon as practicable thereafter. 

  

	27.12	Relationship of the Parties 

 The Parties are independent contractors. Nothing in this
Agreement creates a partnership, joint venture or agency relationship between the Parties and neither Party shall have any fiduciary duty to the other in connection with this Agreement. Except as otherwise expressly provided in this Agreement,
nothing grants either Party the authority to bind or contract any obligation in the name or on the account of the other Party or to make any statement, representation, warranty or commitment on behalf of the other Party. All persons employed by a
Party shall be employees of such Party and not of the other Party and all costs and obligations incurred by reason of any such employment shall be for the account and expense of such Party. 

 

	27.13	Severability 

 To the extent permitted by law, the Parties waive any provision of law
that would render any provision in this Agreement invalid, illegal or unenforceable. If any provision of this Agreement is held to be invalid, illegal or unenforceable, then such provision will be given no

  
 34 

 
effect by the Parties and shall not form part of this Agreement. Provided that the rights and obligations of each Party are not materially and adversely affected, all other provisions of this
Agreement shall remain in full force and effect and the Parties will use their best efforts to negotiate a provision in replacement of the provision held invalid, illegal or unenforceable that is consistent with applicable law and achieves, as
nearly as possible, the original intention of the Parties. 
  

	27.14	Waiver and Non-Exclusion of Remedies 

  

	 	(A)	A Party’s delay or failure to enforce any provision of this Agreement, or to exercise any right or remedy shall not constitute a waiver of that provision, right or remedy or prevent such Party from enforcing any or
all provisions of this Agreement and exercising any rights or remedies in the future. To be effective any waiver must be in writing. The doctrine of affirmation of contract by election shall not apply to this Agreement. 

 

	 	(B)	No remedy conferred by any provision of this Agreement is intended to be exclusive of any other remedy except as expressly provided for in this Agreement and each and every remedy shall be cumulative and shall be in
addition to every other remedy given in this Agreement or existing at law or in equity, by statute or otherwise. 

 [Remainder
of this page intentionally left blank.] 

  
 35 

					
	SIGNED for and on behalf of XDx, Inc.	 		  	SIGNED for and on behalf of Diaxonhit
		 		  	
	 /s/ Peter Maag
	 		  	 /s/ Loïc Maurel

	Name: Peter Maag	 		  	Name: Loïc Maurel
	Title:   Chief Executive Officer	 		  	Title:   President of the Management Board

  
 36 

 Schedule 1 

Patent and/or Patent Applications 
  

									
	 Country
	  	Patent No.
App No.	  	Application
Date	  	 Title
	  	Status
	 European Patent Office
	  	 EP 1585972 
 EP 037997558
	  	4/24/2003	  	METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING TRANSPLANT REJECTION	  	Granted
					
	 European Patent Office
	  	 EP 2194145 
 EP 08016970.9
	  	9/26/2008	  	METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING TRANSPLANT REJECTION	  	Granted
					
	 European Patent Office
	  	 EP 2253719 
 EP 10157687.4
	  	4/24/2003	  	METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING TRANSPLANT REJECTION	  	Granted
					
	 European Patent Office
	  	 EP 2292786 
 EP 10183179.0
	  	4/24/2003	  	METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING TRANSPLANT REJECTION	  	Granted
					
	 European Patent Office
	  	 EP 1885889 
 EP 06770255.5
	  	5/11/2006	  	METHODS OF MONITORING FUNCTIONAL STATUS OF TRANSPLANTS USING GENE PANELS	  	PENDING

  
 1 

 ***Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
  

 Schedule 2 

Part A — Products and Purchase Prices 
  

			
	 Product
	 	 Purchase Price*

	AlloMap Plates	 	€[***] per AlloMap plate for first [***] plates; €[***] per AlloMap plate thereafter
		
	AlloMap Sample Processing/Collection Kits	 	€[***] for box of [***] units to process blood specimens for up to [***] Tests
		
	AlloMap Shipper Kits	 	€[***] each
		
	CPT Tubes	 	€[***] for each box of [***] CPT tubes

  

	*	Prices exclude shipping costs and are converted at €1 to $1.3 and rounded to the nearest Euro; prices quoted for sample processing kits, shipper kits and CPT tubes are at XDx current costs 

PART B — SPECIFICATIONS 
 AlloMap Plates: [***] well
PCR plates that contain probes, primers and the enzyme required for the qRT-PCR step of the Test. Each plate allows testing of up to [***] samples. 

AlloMap Sample Processing/Collection Kits: Required reagents and disposables used to process peripheral blood collected in CPT tubes into a stabilized
mononuclear cell lysate. Processing of the blood specimen is performed at the draw site. Lysates are then frozen and shipped on dry ice to the laboratory which will conduct the Test. 

AlloMap Shipper Kits: Insulated boxes and outer carton, along with requisite forms and labels used to transport frozen patient lysates from the draw
site to the laboratory that will conduct the Test. 
 CPT Tubes: An evacuated tube, which is intended for the collection of whole blood and the
separation of mononuclear cells in a single centrifugation step. The tubes contain a density gradient fluid which facilitates the isolation of mononuclear cells from peripheral blood specimens. The CPT tube is required for the collection of blood
specimens to be used for the Test. 
 Test: The Test is a panel of 20 gene assays, 11 informative and 9 used for normalization and/or quality
control, which produces gene expression data used in the calculation of an AlloMap test Score. The AlloMap score ranges from 0-40. The test is based on standard quantitative real-time polymerase chain reaction methodology (qRT-PCR) using RNA
isolated from peripheral blood mononuclear cells (PBMC) isolated from whole blood collected in a BD Vacutainer CPTTM Cell 

  
 2 

 
Preparation tube (Becton Dickinson, NJ) with sodium citrate (CPTTM tube). Testing is performed according to detailed instructions and conditions provided by XDx to Diaxonhit and/or the Dausset
Lab, including the selection and use of laboratory equipment and testing reagents, and procedures to be followed in order to achieve the required test performance. 

  
 3 

 Schedule 3 

Trademarks 
  

											
	50661-24001.43	 	European Community	 	003923984	 	7/8/2004	 	ALLOMAP	 	Registered
						
	50661-24001.50	 	European Community	 	004439287	 	5/10/2005	 	ALLOMAP	 	Registered

  
 4 

 ***Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
  

 Schedule 4 

Issue of DHT Shares 
 For the payments (if
any) to be made in DHT Shares to XDx pursuant to clauses 3.1 and 3.2, Diaxonhit shall, subject to the approval by its shareholders’ meeting in accordance with applicable French law and the delivery by the appraiser (commissaire aux avantages
particuliers) to be appointed on May 22nd, 2013 by order of the president of the commercial court of Paris (president du Tribunal de commerce de Paris) of its report without
reserve, issue for free [***] ([***]) warrants (bons de souscription d’actions ordinaires) to XDx as follows: 
  

	 	1.	for payment (if any) of the Initial Equity Payment by Diaxonhit (i.e., €387,500 in DHT Shares), [seven hundred seventy five] ([775]) warrants (bons de souscription d’actions ordinaires) (the
“Initial Warrants”). Subject to satisfaction of the CE Approval, each Initial Warrant shall allow XDx to subscribe, at the Market Price (as defined below), a number “N” (as defined below) of new DHT Shares calculated as
follows: 

  

	 	2.	for payment (if any) of the Milestone 1 Equity Payment by Diaxonhit (i.e., €[***] in DHT Shares), [***] ([***]) warrants (bons de souscription d’actions ordinaires) (the “M1 Warrants”).
Subject to satisfaction of the Milestone 1, each M1 Warrant shall allow XDx to subscribe, at the Market Price, a number “N” of new DHT Shares calculated as follows, 

 

	 	3.	for payment (if any) of the Milestone 2 Equity Payment by Diaxonhit (i.e., €[***] in DHT Shares), [***] ([***]) warrants (bons de souscription d’actions ordinaires) (the “M2 Warrants”).
Subject to satisfaction of the Milestone 2, each M2 Warrant shall allow XDx to subscribe, at the Market Price, a number “N” of new DHT Shares calculated as follows, 

 

	 	4.	for payment (if any) of the Milestone 3 Equity Payment by Diaxonhit (i.e., €[***] in DHT Shares), [***] ([***]) warrants (bons de souscription d’actions ordinaires) (the “M3 Warrants”).
Subject to satisfaction of the Milestone 3, each M3 Warrant shall allow XDx to subscribe, at the Market Price, a number “N” of new DHT Shares calculated as follows, 

 

	 	5.	for payment (if any) of the Milestone 4 Equity Payment by Diaxonhit (i.e., €[***] in DHT Shares), [***] ([***]) warrants (bons de souscription d’actions ordinaires) (the “M4 Warrants”
and, together with the Initial Warrants, the M1 Warrants, the M2 Warrants and the M3 Warrants, the “Warrants”). Subject to satisfaction of the Milestone 4, each M4 Warrant shall allow XDx to subscribe, at the Market Price, a number
“N” of new DHT Shares calculated as follows, 

 provided that: 

 

	 	(i)	The total number “N” of new DHT Shares which can be subscribed upon exercise of a Warrant shall be calculated as follows: 

  
 5 

 ***Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
  

 N = [***] / MP 

where “MP” is equal to the Market Price calculated as at the date of exercise of the relevant Warrant, 

provided that the maximum number of new DHT Shares which can be subscribed upon exercise of a Warrant shall not exceed [***] DHT
Shares. Accordingly, in case “N” is higher to [***], “N” shall be equal to [***]; 
  

	 	(ii)	“Market Price” means the subscription price of each DHT Share to be subscribed upon exercise of a Warrant equal to the greater of: (i) the par value of a share of Diaxonhit as at the date of
exercise of the relevant Warrant (i.e., €[***] on the Effective Date) and (ii) the volume weighted average price (VWAP) of a share of Diaxonhit on the Altemext market (or such other market on which the shares of Diaxonhit would be listed
at the time of exercise) during the 20 trading days preceding immediately the date of the CE Notification or relevant Milestone Notification (as defined in clause 3.7), as applicable; 

 

	 	(iii)	The total exercise price (prix d ‘exercice) of the DHT Shares (i.e., EUR [***]) issued upon exercise of a Warrant will be fully paid-up by way of offset against the amount of the Initial Equity Payment or
the Milestone 1/2/3/4 Equity Payment, as applicable; for the purpose of this paragraph (iii), upon satisfaction of the CE Approval, Milestone 1, Milestone 2, Milestone 3 or Milestone 4, as applicable, pursuant to the terms and conditions of this
Agreement, the full amount of the Initial Equity Payment or the Milestone 1/2/3/4 Equity Payment, as applicable, shall become automatically due and payable (liquide et exigible) to XDx. 

The terms and conditions of the Warrants (including, in particular, their duration) are further set forth in the resolutions of the shareholders’ meeting
and board’s meeting (the “Resolutions”) of Diaxonhit, a draft of which is appended to this Schedule 4. 
 Diaxonhit undertakes and
agrees that it shall convene its shareholders to a meeting to approve the Resolutions and issue the Warrants on June 20, 2013. 

  
 6 

 ***Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
  

 Resolutions 

Translation for information purpose only — Only the French version prevails. 

 

			
	 Treizieme résolution : Délégation de competénce
consentie au Directoire pour emettre un nombre maximum de 2.075 bons de souscription d’actions au profit d’une personne nommement designée
  

L’assemblee generale, statuant aux conditions de quorum et de majority d’une assemblee generale extraordinaire, connaissance prise du rapport du
Directoire, du rapport special des Commissaires aux Comptes et du rapport du Commissaire aux avantages particuliers, conformement aux dispositions des articles L. 225-129-2, L. 225-138 et L. 228-91 et suivants du Code de commerce, constatant que le
capital de la Societe est entierement libere ;
  
 1. Délégue au
Directoire, avec faculté de subdelegation clans les conditions légales et réglementaires, sa competence pour decider l’émission, en une ou plusieurs fois, d’un nombre maximum de [***] ([***]) bons de
souscription d’actions (les « BSA ») ;
  
 2. Décide de
supprimer le droit préférentiel de souscription des actionnaires aux BSA et de réserver le droit de souscrire ces BSA a :
  

La societe XDx, Inc., société de l’Etat du Delaware, Etats-Unis, dont le principal etablissement est situe au 3260 Bayshore Blvd, Brisbane
Californie 94005 (ci-apres « XDx ») ;
  
 3. Constate que
conformément aux dispositions de Particle L. 225-132 du Code de commerce, Pemission des BSA
	  	 Thirteenth
resolution: Delegation of competence to the Management Board for the issue of a maximum number of 2,075 warrants in favor of a specific person
  

The general meeting, stating at the quorum and majority conditions of an extraordinary general meeting, notice taken of the Management Board’s report, the
Auditors’ special report and the Appraiser’s report, in accordance with articles L. 225-129-2, L. 225-138 and L. 228-91 and following of the Commercial Code, noting that the share capital is entirely paid up;

 
 1. Delegates to the Management Board, with the possibility to subdelegate within the
legal and regulatory conditions, its competence to decide the issue, in one or several times, a maximum number of [***] ([***]) warrants giving a right to shares (the “Warrants”);

 
 2. Decides to cancel the shareholders’ preferential subscription right to the
Warrants and to reserve the subscription right on these Warrants to :
  
 The company XDx,
Inc., a company registered in the State of Delaware, United-States, which main office is located 3260 Bayshore Blvd, Brisbane California 94005 (below « XDx ») ;

 
 3. Acknowledges that, pursuant to the

  
 7 

 ***Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
  

			
	 emporte de plein droit
renonciation des actionnaires a leur droit preferentiel de souscription aux actions qui pourront etre souscrites par exercice des BSA ;
  

4. Decide que les BSA presenteront notamment les caractetistiques suivantes :
  

Cessibilité
  

Les BSA seront incessibles, a l’exception d’une ou plusieurs cessions a toute societe dont XDx detiendrait le controle ou par laquelle elle serait
controlee, directement ou indirectement, au sens des articles L. 233-3 et L. 233-4 du Code de commerce.
  

Inscription en compte
  

Les BSA seront inscrits au nominatif pur au nom de leur titulaire. Ils ne feront pas l’objet d’une admission aux negociations sur le marche Alternext
de NYSE-Euronext.
  
 Prix d’emission

 
 L’emission des BSA interviendra a titre gratuit.

 
 Date d’emission

 
 Les BSA devront etre anis clans un delai maximum de six mois a compter de la presente
assemblee.
  
 Parite d’exercice, prix d’exercice et nombre maximum
d’actions emises
  
 Chaque BSA donnera le droit de souscrire pour un prix global
d’exercice de [***] euros un nombre d’actions egal a la contre-valeur de [***] euros en actions Diaxonhit.
	  	 Article L. 225-132
of the Commercial Code, the issue of Warrants results in an automatic waiver by existing shareholders of their preferential subscription right on shares issued upon exercise of the Warrants.

 
 4. Decides that the Warrants will have notably the following characteristics:

 
 Transfer:
  

The Warrants may not be transferred, except for one or more transfers to any company that XDx would hold or by which XDx would be held, directly or indirectly,
pursuant to Articles L. 233-3 and L. 233-4 of the Commercial Code.
  
 Book
registration
  
 The Warrants will be in registered form in the name of their holder. No
request for listing on Alternext of NYSE Euronext will be made.
  
 Issue price

 
 The warrants will be issued freely.

 
 Date of the issue

 
 The warrants will have to be issued within six months following this meeting.

 
 Parity of exercise, exercise price, and maximum number of issued shares

Each Warrant gives right to subscribe at a global exercise price of [***] euros, to a number of Diaxonhit shares equal to [***] euros.

This consideration will be calculated on the basis of the average weighted by the volume of Diaxonhit share price on NYSE Alternext market in Paris during the
last twenty (20) stock exchange sessions, it being specified that, in accordance with the law, the subscription price per share cannot be less than the nominal value of the share, i.e. [***] euros, corresponding to a maximum number of [***] shares
that may be issued

  
 8 

 ***Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
  

			
	 Cette contre-valeur sera calculee sur la base de la moyenne ponder& par les volumes
des cours de l’action Diaxonhit sur le mantle NYSE Alternext a Paris pendant les vingt (20) seances de bourse precedant la decision d’exercice des BSA, etant precise que, conformement a la loi, le prix de souscription par action ne pourra
etre infetieur a la valeur nominale de l’action, soit [***] euros, correspondant a un nombre maximum de [***] actions susceptibles d’être emises par exercice d’un BSA, soit une augmentation de capital totale d’un montant
nominal maximum de [***] euros si tous les BSA etaient exerces a ce prix.
  
 Rompus

 
 Lorsque le titulaire de BSA aura droit a un nombre d’actions ordinaires formant
« rompu », it lui sera attribue le nombre entier d’actions immediatement inferieur.
  

Souscription
  

Les actions ordinaires souscrites en exercice des BSA devront etre integralement liberties, tant du nominal que de la prime, lors de leur souscription par
versement en numeraire et/ou par compensation de creances liquides et exigibles detenues sur la Societe. L’exercice des BSA se fera sans frais pour leur titulaire autre que la liberation du prix de souscription des actions ordinaire nouvelles a
emettre en consequence.
  
 Petiode d’exercice et date d’echeance

 
 Les BSA seront exergables a compter de leur emission et pendant une petiode de dix ans a
compter de ladite emission. A defaut d’avoir ete exerces dans ce delai, les BSA seront de plein droit caducs et sans valeur.
	  	 following the
exercise of one Warrant, i.e. a total capital increase of a maximum nominal value of [***] if all the Warrants would be exercised at this price.
  

Fraction of shares
 When the holder of Warrants will have a right
to a fractional number of ordinary shares, he will be granted the immediately lower number of shares.
  

Subscription
 The ordinary shares subscribed upon exercise of the
Warrants will have to be entirely paid up, for the nominal value and the premium, at the time of their subscription by cash payment and/or by compensation with liquidated and due claim on the Company. The exercise of the Warrants will be done
without fees for their holder other than the subscription price of the corresponding new shares.
  

Period of exercise and maturity date
 The Warrants can be
exercised as of their issue and for a period of ten years following their issue. If not exercised within this period, the Warrants will be automatically null and void and without value.

 
 Form

The new ordinary shares issued upon exercise of the Warrants will be ordinary shares, in bearer or registered form depending on the subscriber’s choice,
and a request for listing on Alternext of NYSE Euronext will be made.
  
 Dividends

The new ordinary shares issued upon exercise of the Warrants will be entirely assimilated to existing ordinary shares and will give right to dividends on the
first day of the pending fiscal period.

  
 9 

			
	 Forme

Les actions ordinaire nouvelles emises au resultat de l’exercice des BSA seront des actions ordinaires et revetiront la forme
nominative ou au porteur au choix du souscripteur et feront l’objet d’une demande d’admission aux negociations sur le marche Alternext de NYSE-Euronext.
  

Jouissance
 Les actions
ordinaires nouvelles emises au resultat de l’exercice des BSA seront entierement assimilees aux actions ordinaires anciennes et porteront jouissance au premier jour de l’exercice en cours.

 
 5. Approuve les avantages particuliers qui resulteront de
l’emission des BSA au profit de XDx ;
  
 6. Delegue au
Directoire tous pouvoirs, avec faculte de subdelegation clans les conditions legales et reglementaires, pour mettre en oeuvre la presente delegation et proceder a l’emission des BSA - ainsi que le cas echeant d’y surseoir - clans les
conditions et limites fixees a la presente resolution, et notamment a l’effet de :
  

•   proceder a l’emission de toute ou partie des BSA dans les conditions et limites ci-dessus
;
  
 •   determiner les
autres conditions des BSA, notamment les conditions d’exercice, ainsi que la realisation de ces conditions et la recevabilite de l’exercice des BSA ;
	  	 5. Approves the
specific advantages that will result from the issue of Warrants to XDx;
  
 6. Delegates
to the Management Board all powers, with the possibility of subdelegation within legal and regulatory limits, to implement this delegation and perform the issue of Warrants — and possibly to postpone such issue(s) - in accordance with the
conditions and limits set in this resolution, including:
  

•   proceed with the issue of all or a part of the Warrants within the hereabove conditions and
limits;
  
 •   set the other
conditions of the Warrants, notably the conditions of exercise, together with the completion of these conditions and the admissibility of the Warrants exercise ;
  

•   set the number and the subscription price of the shares to be issued upon exercise of the
Warrants, under the hereabove conditions;
  

•   set the terms and conditions to protect the rights of Warrants holders pursuant to legal rules
and/or contractual stipulations; to take all necessary measures in due course to protect the rights of Warrants holders;
  

•   as the case may be, suspend the exercise of the Warrants for a period that cannot exceed three
months;
  
 •   acknowledge
the exercise of the Warrants and the subsequent share capital increases; subsequently amend the bylaws and proceed with all necessary formalities related to these capital increases;

  
 10 

			
	 •   determiner le nombre et
le prix de souscription des actions a emettre sur exercice des BSA dans les conditions determines ci-dessus ;
  

•   determiner les conditions et modalites de la preservation des droits du porteur de BSA en
application des dispositions legales et/ou contractuelles ; de prendre en temps utile toute mesure qui s’avererait necessaire pour preserver les droits du porteur de BSA ;
  

•   suspendre le cas echeant l’exercice des BSA pendant un delai qui ne pourra exceder trois
mois ;
  
 •   constater
l’exercice des BSA anis et les augmentations consecutives du capital social ; modifier correlativement les statuts et effectuer toutes formalites relatives auxdites augmentations du capital ;

 
 •   modifier les statuts de
la Societe afire, le cas echeant, de stipuler les avantages particuliers que le commissaire aux avantages particuliers pourrait, le cas echeant, constater ;
  

•   requetir l’admission aux negociations sur le marche Alternext des actions ordinaires
resultant de l’exercice des BSA ;
  

•   et d’une maniere generale, faire tout ce qui sera necessaire en vue de l’emission
des BSA et des actions resultant de l’exercice des BSA.
	  	
•   amend the Company bylaws in order to mention, as the case may be, the specific advantages that
the Appraiser could point out;
  

•   request the admission for listing on Alternext of the ordinary shares resulting from the
exercise of the Warrants;
  

•   and, more generally, take all necessary measures in order to issue the Warrants and the shares
resulting from the exercise of the Warrants.

  
 11 

 ***Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
  

 Schedule 5 

Sample Products 
 [***]
AlloMap Plates (as per the terms contained herein) 
 [***] AlloMap Shipper Kits 

[***] AlloMap Sample Processing/Collection Kits 

  
 12 

 Schedule 6 

Governance of Collaboration Committee 

PURSUANT TO CLAUSE 6.5 

1. Within 30 days from the Effective Date, the Parties will establish a Governance of Collaboration Committee (“the
Collaboration Committee”) comprising two (2) voting representatives of each Party. Each Party may at any time appoint different representatives by prior written notice to the other Party. Additional representatives of a Party may
attend meetings in a non-voting capacity. Each Party will designate one of its representatives as a co-chair of the Committee. 
 2.
The Collaboration Committee will determine the commercialization strategy, monitor and manage the activities conducted pursuant to this Distribution and Licensing Agreement, and establish priorities and responsibilities regarding the key
elements of the promotional, marketing and sales activities. 
 3. The Collaboration Committee will hold meetings at least once every
quarter by teleconference or in person at such times and places as the co-chairs may determine, provided that they will meet in person at least once per year, alternating between the head offices of each Party. All other meetings need not be in
person and may be by teleconference or other method. Each Party will bear its own costs associated with attending meetings. 
 4.
Decisions of the Collaboration Committee will require unanimous consent to be binding. A voting representative of one Party may assign to a voting representative of the same Party the ability to give consent by proxy. If the Collaboration
Committee is unable to reach unanimous consent on an issue, it will submit the issue to the Chief Executive Officer of each Party, who will confer; should these persons fail to agree, the Collaboration Committee will defer to the decision of a
mediator or an independent expert, as appropriate to the nature of the dispute. Cost of the expertise will be shared equally between the Parties. 

5. The Collaboration Committee will keep accurate minutes of its deliberations and will fmalize them for release to the Parties within
ten (10) days of each meeting. 
 6. Each Party will promptly disclose to the other Party and to the Collaboration Committee in
reasonable details all information that is necessary or reasonably useful for the other Party to perform its obligations under the Agreement. The Parties will provide the Collaboration Committee with reasonable access to records of the Parties,
relating to the performance of the Agreement that the Collaboration Committee may reasonably require, except where such access is inconsistent with a Party’s duty of confidentiality to a third party. 

7. Each Party will timely report to the other Party or to the Collaboration Committee significant events or information concerning the
performance of this Agreement, including the Testing Services Agreement, Agents and Sub-Distributors. 

  
 13 

 Schedule 7 

Designated Products 
 Test, AlloMap
plates, AlloMap sample processing kit and LTP. “LTP” means a positive PCR control used in each well of the AlloMap plates. 

  
 14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}]]